<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Brief Funct Genomics</journal-id><journal-id journal-id-type="iso-abbrev">Brief Funct Genomics</journal-id><journal-id journal-id-type="publisher-id">bfgp</journal-id><journal-title-group><journal-title>Briefings in Functional Genomics</journal-title></journal-title-group><issn pub-type="ppub">2041-2649</issn><issn pub-type="epub">2041-2657</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30785618</article-id><article-id pub-id-type="pmc">6609535</article-id><article-id pub-id-type="doi">10.1093/bfgp/elz002</article-id><article-id pub-id-type="publisher-id">elz002</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Paper</subject></subj-group></article-categories><title-group><article-title>Interplay between miRNAs and host genes and their role in cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Baohong</given-names></name><!--<email>liubaohong@caas.cn</email>--><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Shyr</surname><given-names>Yu</given-names></name><!--<email>yu.shyr@vanderbilt.edu</email>--><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Cai</surname><given-names>Jianping</given-names></name><!--<email>caijianping@caas.cn</email>--><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Qi</given-names></name><!--<email>qi.liu@Vanderbilt.edu</email>--><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref rid="cor1" ref-type="corresp"/></contrib></contrib-group><aff id="aff1"><label>1</label>State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Parasitology of Gansu Province, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu Province, China</aff><aff id="aff2"><label>2</label>Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN, USA</aff><aff id="aff3"><label>3</label>Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA</aff><aff id="aff4"><label>4</label>Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, China</aff><author-notes><corresp id="cor1">Corresponding author: Qi Liu, Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN 37232; USA. Tel.: (615) 322-6618; Fax: +1 615 936-2602; E-mail: <email>qi.liu@vanderbilt.edu</email>, Baohong Liu, State Key Laboratory of Veterinary Etiological Biology; Key Laboratory of Veterinary Parasitology of Gansu Province; Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu Province, China. Tel: +86 9318342580; Fax: +86 931834097; E-mail: <email>liubaohong@caas.cn</email></corresp></author-notes><pub-date pub-type="collection"><month>7</month><year>2019</year></pub-date><pub-date pub-type="epub" iso-8601-date="2019-02-20"><day>20</day><month>2</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>2</month><year>2019</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>18</volume><issue>4</issue><fpage>255</fpage><lpage>266</lpage><history><date date-type="received"><day>28</day><month>9</month><year>2018</year></date><date date-type="rev-recd"><day>21</day><month>11</month><year>2018</year></date><date date-type="accepted"><day>23</day><month>1</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2019. Published by Oxford University Press.</copyright-statement><copyright-year>2019</copyright-year><license license-type="cc-by" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="elz002.pdf"/><abstract><title>Abstract</title><p>MicroRNAs (miRNAs) are small endogenous non-coding functional RNAs that post-transcriptionally regulate gene expression. They play essential roles in nearly all biological processes including cell development and differentiation, DNA damage repair, cell death as well as intercellular communication. They are highly involved in cancer, acting as tumor suppressors and/or promoters to modulate cell proliferation, epithelial-mesenchymal transition and tumor invasion and metastasis. Recent studies have shown that more than half of miRNAs are located within protein-coding or non-coding genes. Intragenic miRNAs and their host genes either share the promoter or have independent transcription. Meanwhile, miRNAs work as partners or antagonists of their host genes by fine-tuning their target genes functionally associated with host genes. This review outlined the complicated relationship between intragenic miRNAs and host genes. Focusing on miRNAs known as oncogenes or tumor suppressors in specific cancer types, it studied co-expression relationships between these miRNAs and host genes in the cancer types using TCGA data sets, which validated previous findings and revealed common, tumor-specific and even subtype-specific patterns. These observations will help understand the function of intragenic miRNAs and further develop miRNA therapeutics in cancer.</p></abstract><kwd-group><kwd>miRNA</kwd><kwd>intragenic miRNA biogenesis</kwd><kwd>host genes</kwd><kwd>interplay</kwd><kwd>cancer</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><named-content content-type="funder-name">Innovative Special Project of Agricultural Sci-Tech</named-content></funding-source><award-id>CAASASTIP-2014-LVRI-09</award-id></award-group></funding-group><counts><page-count count="12"/></counts></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>MicroRNA (miRNA) is a class of small endogenous non-coding RNAs with a length between 20 and 24 nucleotides. They recognize and bind mRNA transcripts in a sequence-specific mode, resulting in degradation or translational repression of the corresponding mRNAs [<xref rid="ref1" ref-type="bibr">1</xref>, <xref rid="ref2" ref-type="bibr">2</xref>]. The generation of miRNA from primary miRNA is a multi-step but fairly well understood process. After cleavage of primary transcripts to form precursor miRNAs in the nucleus, precursor miRNAs are exported into the cytoplasm for additional cleavage by an enzyme called Dicer to produce single-stranded mature miRNAs. Mature miRNAs are then loaded onto the RNA-induced silencing complex where they bind to 3&#x02032;-UTR
sequences of target genes. If the 3&#x02032;-UTR of the target mRNA is fully complementary to the miRNA seed site, the mRNA is targeted for degradation. If it is partially complementary to the miRNA, the mRNA is targeted for translational inhibition [<xref rid="ref3" ref-type="bibr">3&#x02013;5</xref>]. In this way, an individual miRNA can post-transcriptionally regulate expression of hundreds of mRNAs, which profoundly alter gene expression and drive cells toward transformation.</p><p>Cancer is a complex disease involving multiple genes and pathways; therefore, it is not very useful to target one single gene for cancer treatment. A single miRNA can regulate expression of hundreds of genes involved in distinct cellular functions, which makes miRNAs the promising therapeutic targets. Since the miRNA dysregulation in cancer was first reported in 2002 [<xref rid="ref6" ref-type="bibr">6</xref>], many studies have found miRNAs&#x02019; function in carcinogenesis including tumor suppressor miRNAs (ts-miRs) and
oncogenic miRNAs (onco-miRs). The upregulated onco-miRs and downregulated ts-miRs lead to cancer initiation and progression [<xref rid="ref7" ref-type="bibr">7</xref>, <xref rid="ref8" ref-type="bibr">8</xref>]. These miRNAs have attracted lots of attention as biomarkers and therapeutic targets. Controlling miRNAs transcriptional regulation by genome or RNA-editing tool has become a novel and promising approach [<xref rid="ref9" ref-type="bibr">9</xref>, <xref rid="ref10" ref-type="bibr">10</xref>].</p><p>Although there is a general understanding of the generation of mature miRNA from primary miRNA, the transcriptional regulation of primary miRNAs is still unclear. The location of miRNAs is one major factor that determines how primary miRNAs are transcriptionally regulated. According to their genomic position, miRNAs can be classified into intragenic and intergenic miRNAs. Intragenic miRNAs, embedded within introns or exons of genes on the same strand, are believed to be co-regulated with their host genes by Pol II, whereas intergenic miRNAs, located between genes, are transcribed from their own Pol II or Pol III promoters. Recent studies, however, revealed that intragenic miRNAs, even intronic miRNAs, are not always co-transcribed with their host genes [<xref rid="ref11" ref-type="bibr">11</xref>, <xref rid="ref12" ref-type="bibr">12</xref>]. Some intronic miRNAs have been found to interact with their host genes to affect their stability [<xref rid="ref13" ref-type="bibr">13</xref>, <xref rid="ref14" ref-type="bibr">14</xref>]. More importantly, bioinformatics studies predicted that approximately 20% of intronic miRNAs target host mRNA transcripts in a feedback loop [<xref rid="ref13" ref-type="bibr">13&#x02013;15</xref>].</p><p>In this review, we outlined the complicated relationships between miRNAs and their host genes. Focusing on onco-miRs and ts-miRs in specific cancer types, we studied co-expression relationships between these miRNAs and host genes using TCGA data sets. We not only found common co-expression patterns, but also revealed tumor-specific and even subtype-specific relationships, which are very helpful for understanding transcriptional and post-transcriptional regulation of miRNAs and further developing miRNA therapeutics in cancer.</p><sec id="sec3"><title>Definition of intragenic miRNAs and their host genes</title><p>Location of miRNAs is one of the hot topics in miRNA research since it is a major factor to determine how miRNAs are regulated. Based on their location, miRNAs can be classified into intragenic miRNAs and intergenic miRNAs. miRNAs located within protein-coding or non-coding genes are called intragenic miRNAs, while the genes in which the miRNAs are embedded are called host genes. Intragenic miRNAs can be further categorized into intronic miRNAs (miRNAs located in intronic regions), exonic miRNAs (miRNAs located in exonic regions), junction miRNAs (miRNAs located in gene intron&#x02013;exon junctions) and antisense miRNAs (miRNAs located in the antisense strand of gene) (<xref rid="f1" ref-type="fig">Figure 1</xref>). Intergenic miRNAs, located between genes, are believed to be transcribed from their own Pol II or Pol III promoters. However, recent studies revealed that there is a small percentage of intergenic miRNAs that are potentially co-transcribed with their neighboring genes through two mechanisms. One mechanism is called readthrough, where the transcription of one gene continues beyond the normal transcription termination site into intergenic regions. miRNAs located in the immediate (&#x0003c;4000&#x000a0;bp) downstream sense region of protein-coding or non-coding genes are likely to be transcribed by readthrough
transcription [<xref rid="ref16" ref-type="bibr">16</xref>] (<xref rid="f1" ref-type="fig">Figure 1E</xref>). The other is called divergent transcription, defined as two polymerases transcribing on both sense and antisense directions from the same promoter. As a common feature for active promoters, divergent transcription generates long non-coding antisense transcripts coupled to active gene promoters [<xref rid="ref16" ref-type="bibr">16&#x02013;18</xref>] (<xref rid="f1" ref-type="fig">Figure 1F</xref>). These two types of intergenic miRNAs (readthrough or divergent) can be classified into `intragenic&#x02019; category as well since they potentially share the same promoter with their neighboring genes, which are different from other intergenic miRNAs in transcriptional regulation. The neighboring genes that miRNAs are potentially co-transcribed with can also be called `host&#x02019; genes.</p><fig id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Intragenic miRNA classification. miRNA categories are defined based on their locations relative to exon, intron and gene regions.</p></caption><graphic xlink:href="elz002f1"/></fig><fig id="f2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Pie chart of miRNA categories.</p></caption><graphic xlink:href="elz002f2"/></fig><p>Previous studies have reported that more than half of miRNAs are intragenic miRNAs. To facilitate the analysis of genomic and structure features of intragenic miRNAs and host genes, miRIAD (<ext-link ext-link-type="uri" xlink:href="http://www.miriad-database.org">http://www.miriad-database.org</ext-link>) provides a comprehensive knowledge on intragenic miRNAs by collecting public data from multiple sources, such as host gene function, miRNA and host gene expression and miRNA targets [<xref rid="ref19" ref-type="bibr">19</xref>]. As gene annotation is improved and new miRNAs are identified, more intragenic miRNAs are classified [<xref rid="ref20" ref-type="bibr">20</xref>]. To date, there are 1881 miRNAs in miRBase v21 [<xref rid="ref21" ref-type="bibr">21&#x02013;25</xref>]. Based on their relative location to protein-coding or non-coding genes (<xref rid="f1" ref-type="fig">Figure 1</xref>), 1434 can be classified as intragenic miRNAs, among which 918 (48.8%), 74 (3.9%), 45 (2.4%), 59 (3.1%), 50 (2.6%), 198 (10.5%) are intronic, exonic, junction, readthrough, divergent and antisense miRNAs, respectively (<xref rid="f2" ref-type="fig">Figure 2</xref>). There are 90 miRNAs (4.8%), which can not be assigned into one specific category. For example, an miRNA is located within the intron region of one transcript and also embedded in exon regions of another transcript. In this case, this miRNA is assigned into a `mixed&#x02019; category (<xref rid="f2" ref-type="fig">Figure 2</xref>).</p></sec><sec id="sec4"><title>Interplay between intragenic miRNAs and their host genes</title><p>Early evidence proposed a co-expression model suggesting that intronic miRNAs are derived from the same primary transcripts as their host genes. Intronic miRNAs use the transcriptional start sites (TSSs) of their host genes to initiate transcription. The primary transcript is then processed into mRNA and miRNAs by microprocessor and splicing. There is no interplay between microprocessor cleavage and splicing, resulting in the co-expression between miRNA and mRNA [<xref rid="ref26" ref-type="bibr">26&#x02013;28</xref>]. For example, the expression levels of miR-335 significantly correlated with <italic>MEST</italic> in 21 HCC cell lines, supporting the notion that the intronic miRNA is co-expressed with its host gene under the regulation of the host gene promoter [<xref rid="ref29" ref-type="bibr">29</xref>]. Strongly correlated expression profiles between 175 miRNAs and their host genes across 24 different human organs have been reported [<xref rid="ref26" ref-type="bibr">26</xref>]. An extreme case of coordination between intronic miRNA processing and splicing happens in very short introns, where the entire intron is so short that it is already a pre-miRNA without the involvement of microprocessor. These short introns, called mirtrons, are highly co-expressed with their host genes [<xref rid="ref30" ref-type="bibr">30</xref>].</p><p>Increasing evidence, however, has shown that intronic miRNAs and host genes are not co-expressed as frequently as we previously expected due to two main reasons [<xref rid="ref31" ref-type="bibr">31</xref>, <xref rid="ref32" ref-type="bibr">32</xref>]. One reason is that miRNAs have their own independent promoters. It has been found that over one-third of intronic miRNAs have their own promoters (Polymerase II or III), whose transcription is independent from their host genes [<xref rid="ref11" ref-type="bibr">11</xref>, <xref rid="ref33" ref-type="bibr">33</xref>]. For example, it has been validated that miR-26b has an independent TSS, promoter signal and transcriptional factor from its host gene <italic>CTDSP</italic> [<xref rid="ref31" ref-type="bibr">31</xref>]. Kim <italic>et al</italic>. [<xref rid="ref34" ref-type="bibr">34</xref>] revealed that the splicing factor SRSF3 regulates the expression of miR-1908 independently from its host gene <italic>FADS1</italic>, suggesting that miR-1908 could be affected by its own transcription unit. Ozsolak <italic>et al</italic>. [<xref rid="ref35" ref-type="bibr">35</xref>] reported that roughly 30% of intragenic miRNAs may be initiated independently
especially if they are resided in large-sized (&#x0003e;5&#x000a0;kbp) intronic segments. The intronic regions are long enough to carry their own transcription units of pre-miRNA genes [<xref rid="ref32" ref-type="bibr">32</xref>]. The other reason is the crosstalk between microprocessor cleavage and splicing [<xref rid="ref36" ref-type="bibr">36</xref>]. In addition, the evolution conservation also contributes to the expression discordance between miRNAs and their hosts. He <italic>et al</italic>. [<xref rid="ref11" ref-type="bibr">11</xref>] reported that evolutionary non-conserved intragenic miRNAs are less co-expressed with host genes than conserved ones. They suggest that most non-conserved miRNAs are expressed serendipitously and weakly but not necessarily always from the same transcripts as the host genes and some are co-expressed owing to shared chromatin dynamics. They then conjecture that for some of these their co-expression is beneficial and selection favors them to be what call &#x02018;embedded&#x02019;, meaning they evolve stronger co-expression, which in turn favors conservation of miRNA target sites on 3&#x02032;-UTRs of desirable target genes [<xref rid="ref11" ref-type="bibr">11</xref>].</p><p>The transcriptional regulation of exonic miRNAs is different from intronic miRNAs since Drosha processing of an exonic miRNA will inhibit production of the spliced host mRNA [<xref rid="ref37" ref-type="bibr">37</xref>, <xref rid="ref38" ref-type="bibr">38</xref>]. Sundaram <italic>et al</italic>. [<xref rid="ref37" ref-type="bibr">37</xref>] showed a clear inverse correlation between the expression pattern of miR-198 and <italic>FSTL1</italic> (host gene), which highlights the importance of this regulatory switch in controlling context-specific gene expression to orchestrate wound re-epithelialization.</p><p>The biogenesis of junction miRNAs is most complicated since there is competition between spliceosome and the microprocessor. When the splicing machinery does not recognize the internal exon, and the microprocessor components, rather than the spliceosome complex, bind to the RNA transcript at the pre-miRNA region to generate pre-miRNA. When the internal exon is recognized through interaction with specific splicing factors, the RNA secondary structure is released and splicing of the internal exon is carried out by the spliceosome before DGCR8 and Drosha bind to the pre-miRNA region. The spliced variant containing the alternative exon is the product and no pre-miRNA is made [<xref rid="ref39" ref-type="bibr">39</xref>]. That is to say, junction miRNA is negatively regulated by splicing. Melamed <italic>et al</italic>. [<xref rid="ref39" ref-type="bibr">39</xref>] studied an miRNA cluster including one exonic miRNA miR-410, one intronic miRNA miR-541 and one junction miRNA miR-412. They confirmed that the splicing and the processing of pre-miRNAs located in exon-intron junctions are mutually exclusive and alternative splicing is inversely correlated with levels of miR-412<bold>.</bold></p><p>Readthrough and divergent miRNAs are special whose transcription is a byproduct of their neighboring genes. Readthrough miRNA is generated by a continuous transcription beyond a normal stop sign from an active gene (<xref rid="f1" ref-type="fig">Figure 1E</xref>). For example, miR-21 is the most commonly over-expressed miRNA in cancer and a proven oncogene. miR-21 is located immediately downstream of the vacuole membrane protein-1 (<italic>VMP1</italic>) gene, which was reported to bypass the polyadenylation signals to include miR-21, thus providing a novel and independently regulated source of miR-21, termed VMP1&#x02013;miR-21 [<xref rid="ref38" ref-type="bibr">38</xref>]. Divergent miRNA is a product of bi-directional transcription of active promoters. In humans, some bidirectional promoter regions transcribing an miRNA and protein-coding gene simultaneously have been experimentally identified, e.g. the BTG4 promoter upstream of miR-34b and miR-34c [<xref rid="ref40" ref-type="bibr">40</xref>], and the <italic>POLR3D</italic> promoter upstream of miR-320a on chromosome 8 [<xref rid="ref41" ref-type="bibr">41</xref>].</p><p>In addition to the transcriptional regulation of intragenic miRNAs by their host genes, host genes are also subject to the regulation of miRNAs. The complicated and mutual regulation between miRNAs and host genes form a negative or positive feedback loop, where miRNAs play an antagonistic or synergetic role as a competitor or partner of a host gene [<xref rid="ref13" ref-type="bibr">13</xref>, <xref rid="ref14" ref-type="bibr">14</xref>]. Bioinformatics studies have demonstrated that approximately 20% of intronic miRNAs were predicted to target their host genes [<xref rid="ref13" ref-type="bibr">13</xref>]. One example is miR-338-3p, which inhibits the transcription of its host gene <italic>AATK</italic> by binding to its 3&#x02032;-UTR [<xref rid="ref42" ref-type="bibr">42</xref>]. Another example is miR-26b, which controls neuronal differentiation by repressing its host transcript, <italic>ctdsp2</italic> [<xref rid="ref43" ref-type="bibr">43</xref>]. Such an interaction forms the `first-order&#x02019; negative-feedback circuit for fine-turning host gene expression. Besides direct regulation, an miRNA can negatively regulate its host gene function by targeting a gene whose product is a downstream effector of the host gene product. Such regulation could be termed `second-order&#x02019; negative feedback. For example, miR-641 is not predicted to target its host, <italic>AKT2</italic>, while its predicted targets, which include <italic>PI3K, EGFR, PTEN, PDK1, RAS, MEK</italic> and <italic>ERK</italic>, are in functional synergy with its host, giving credence to the second-order negative-feedback circuitry line of evidence [<xref rid="ref44" ref-type="bibr">44</xref>].</p><table-wrap id="TB1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Summary of co-expression patterns between onco/ts-miRs and their host genes in specific cancer types</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">
<bold>miR cluster</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>miRNA</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Host</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Loc</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Type</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Cancer</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Correlation in TCGA</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Ref.</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">miR-1</td><td align="left" rowspan="1" colspan="1">miR-1-1</td><td align="left" rowspan="1" colspan="1">MIR1-1HG</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Thyroid; bladder cancer</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">[<xref rid="ref52" ref-type="bibr">52</xref>, <xref rid="ref53" ref-type="bibr">53</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-9</td><td align="left" rowspan="1" colspan="1">miR-9-1</td><td align="left" rowspan="1" colspan="1">C1orf61</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">onco-miR</td><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">0.39<sup>**</sup></td><td align="left" rowspan="1" colspan="1">[<xref rid="ref54" ref-type="bibr">54&#x02013;56</xref>]</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">miR-9-3</td><td align="left" rowspan="1" colspan="1">MIR9-3HG</td><td align="left" rowspan="1" colspan="1">Mix</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Gastric cancer</td><td align="left" rowspan="1" colspan="1">0.25<sup>**</sup></td><td align="left" rowspan="1" colspan="1">[<xref rid="ref56" ref-type="bibr">56</xref>]</td></tr><tr><td align="left" rowspan="2" colspan="1">miR-15/16&#x02013;1</td><td align="left" rowspan="1" colspan="1">miR-15a</td><td align="left" rowspan="2" colspan="1">DLEU2</td><td align="left" rowspan="2" colspan="1">Intron</td><td align="left" rowspan="2" colspan="1">ts-miR</td><td align="left" rowspan="2" colspan="1">CLL</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="2" colspan="1">[<xref rid="ref57" ref-type="bibr">57</xref>, <xref rid="ref58" ref-type="bibr">58</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-16-1</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="6" colspan="1">miR-17-92</td><td align="left" rowspan="1" colspan="1">miR-17</td><td align="left" rowspan="6" colspan="1">C13ORF25</td><td align="left" rowspan="6" colspan="1">Mix</td><td align="left" rowspan="6" colspan="1">onco-miR</td><td align="left" rowspan="6" colspan="1">Lymphomas; lung cancer; renal cell cancer</td><td align="left" rowspan="1" colspan="1">&#x02013;, 0.49<sup>**</sup>, 0.07</td><td align="left" rowspan="6" colspan="1">[<xref rid="ref57" ref-type="bibr">57&#x02013;59</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-18a</td><td align="left" rowspan="1" colspan="1">&#x02013;, 0.48<sup>**</sup>, 0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-19a</td><td align="left" rowspan="1" colspan="1">&#x02013;, 0.50<sup>**</sup>, 0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-20a</td><td align="left" rowspan="1" colspan="1">&#x02013;, 0.55<sup>**</sup>, 0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-19b1</td><td align="left" rowspan="1" colspan="1">&#x02013;, 0.48<sup>**</sup>, 0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-92a1</td><td align="left" rowspan="1" colspan="1">&#x02013;, 0.51<sup>**</sup>, 0.19</td></tr><tr><td align="left" rowspan="7" colspan="1">miR-21</td><td align="left" rowspan="7" colspan="1">miR-21</td><td align="left" rowspan="7" colspan="1">VMP1</td><td align="left" rowspan="7" colspan="1">Read through</td><td align="left" rowspan="7" colspan="1">onco-miR</td><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">0.52<sup>**</sup></td><td align="left" rowspan="7" colspan="1">[<xref rid="ref60" ref-type="bibr">60&#x02013;65</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Lung cancer</td><td align="left" rowspan="1" colspan="1">0.36<sup>*</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Pancreas cancer</td><td align="left" rowspan="1" colspan="1">0.61<sup>**</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Liver cancer</td><td align="left" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastric cancer</td><td align="left" rowspan="1" colspan="1">0.54<sup>**</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Cervical cancer</td><td align="left" rowspan="1" colspan="1">0.39<sup>**</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Hematopoietic cancer</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-23b</td><td align="left" rowspan="1" colspan="1">miR-23b</td><td align="left" rowspan="1" colspan="1">C9ORF3</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Gastric cancer</td><td align="left" rowspan="1" colspan="1">0.65<sup>**</sup></td><td align="left" rowspan="1" colspan="1">[<xref rid="ref66" ref-type="bibr">66</xref>]</td></tr><tr><td align="left" rowspan="2" colspan="1">miR-26a</td><td align="left" rowspan="1" colspan="1">miR-26a-1</td><td align="left" rowspan="1" colspan="1">CTDSPL</td><td align="left" rowspan="2" colspan="1">Intron</td><td align="left" rowspan="2" colspan="1">ts-miR</td><td align="left" rowspan="2" colspan="1">Osteosarcoma; colorectal cancer</td><td align="left" rowspan="1" colspan="1">&#x02013;,&#x02013;</td><td align="left" rowspan="2" colspan="1">[<xref rid="ref67" ref-type="bibr">67&#x02013;69</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-26a-2</td><td align="left" rowspan="1" colspan="1">CTDSP2</td><td align="left" rowspan="1" colspan="1">&#x02013;,&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-26b</td><td align="left" rowspan="1" colspan="1">miR-26b</td><td align="left" rowspan="1" colspan="1">CTDSP1</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Colorectal cancer</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">[<xref rid="ref67" ref-type="bibr">67</xref>, <xref rid="ref69" ref-type="bibr">69</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-27b</td><td align="left" rowspan="1" colspan="1">miR-27b</td><td align="left" rowspan="1" colspan="1">C9ORF3</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Prostate cancer</td><td align="left" rowspan="1" colspan="1">0.62<sup>**</sup></td><td align="left" rowspan="1" colspan="1">[<xref rid="ref60" ref-type="bibr">60</xref>, <xref rid="ref70" ref-type="bibr">70</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-30c</td><td align="left" rowspan="1" colspan="1">miR-30c-1</td><td align="left" rowspan="1" colspan="1">NFYC</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Prostate cancer</td><td align="left" rowspan="1" colspan="1">0.06</td><td align="left" rowspan="1" colspan="1">[<xref rid="ref71" ref-type="bibr">71</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-33a</td><td align="left" rowspan="1" colspan="1">miR-33a</td><td align="left" rowspan="1" colspan="1">SREBF2</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Prostate cancer</td><td align="left" rowspan="1" colspan="1">0.24<sup>**</sup></td><td align="left" rowspan="1" colspan="1">[<xref rid="ref72" ref-type="bibr">72</xref>]</td></tr><tr><td align="left" rowspan="2" colspan="1">miR-34b</td><td align="left" rowspan="2" colspan="1">miR-34b</td><td align="left" rowspan="2" colspan="1">BTG4</td><td align="left" rowspan="2" colspan="1">Divergent</td><td align="left" rowspan="2" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">&#x02212;0.05</td><td align="left" rowspan="2" colspan="1">[<xref rid="ref73" ref-type="bibr">73</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Prostate cancer</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-95</td><td align="left" rowspan="1" colspan="1">miR-95</td><td align="left" rowspan="1" colspan="1">ABLIM2</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">onco-miR</td><td align="left" rowspan="1" colspan="1">Liver cancer</td><td align="left" rowspan="1" colspan="1">0.75<sup>**</sup></td><td align="left" rowspan="1" colspan="1">[<xref rid="ref74" ref-type="bibr">74</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-101</td><td align="left" rowspan="1" colspan="1">miR-101-2</td><td align="left" rowspan="1" colspan="1">RCL1</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Gastric cancer</td><td align="left" rowspan="1" colspan="1">0.17<sup>*</sup></td><td align="left" rowspan="1" colspan="1">[<xref rid="ref75" ref-type="bibr">75</xref>]</td></tr><tr><td align="left" rowspan="3" colspan="1">miR-106b/25</td><td align="left" rowspan="1" colspan="1">miR-106b</td><td align="left" rowspan="3" colspan="1">MCM7</td><td align="left" rowspan="3" colspan="1">Intron</td><td align="left" rowspan="3" colspan="1">onco-miR</td><td align="left" rowspan="3" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">0.68<sup>**</sup></td><td align="left" rowspan="3" colspan="1">[<xref rid="ref76" ref-type="bibr">76</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-93</td><td align="left" rowspan="1" colspan="1">0.57<sup>**</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">miR-25</td><td align="left" rowspan="1" colspan="1">0.66<sup>**</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">miR-107</td><td align="left" rowspan="1" colspan="1">miR-107</td><td align="left" rowspan="1" colspan="1">PANK1</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer</td><td align="left" rowspan="1" colspan="1">0.22<sup>*</sup></td><td align="left" rowspan="1" colspan="1">[<xref rid="ref77" ref-type="bibr">77</xref>]</td></tr><tr><td align="left" rowspan="2" colspan="1">miR-125b</td><td align="left" rowspan="1" colspan="1">miR-125b-1</td><td align="left" rowspan="1" colspan="1">MIR100HG</td><td align="left" rowspan="2" colspan="1">Intron</td><td align="left" rowspan="2" colspan="1">onco-miR</td><td align="left" rowspan="2" colspan="1">Lung cancer</td><td align="left" rowspan="1" colspan="1">0.69<sup>**</sup></td><td align="left" rowspan="2" colspan="1">[<xref rid="ref63" ref-type="bibr">63</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-125b-2</td><td align="left" rowspan="1" colspan="1">MIR99AHG</td><td align="left" rowspan="1" colspan="1">0.77<sup>**</sup></td></tr><tr><td align="left" rowspan="3" colspan="1">miR-126</td><td align="left" rowspan="3" colspan="1">miR-126</td><td align="left" rowspan="3" colspan="1">EGFL7</td><td align="left" rowspan="3" colspan="1">Intron</td><td align="left" rowspan="3" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer</td><td align="left" rowspan="1" colspan="1">0.56<sup>**</sup></td><td align="left" rowspan="3" colspan="1">[<xref rid="ref78" ref-type="bibr">78</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">0.13<sup>*</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Lung cancer</td><td align="left" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="3" colspan="1">miR-128</td><td align="left" rowspan="3" colspan="1">miR-128-1</td><td align="left" rowspan="3" colspan="1">R3HDM1</td><td align="left" rowspan="3" colspan="1">Intron</td><td align="left" rowspan="3" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">AML</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="3" colspan="1">[<xref rid="ref79" ref-type="bibr">79&#x02013;81</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Esophageal cancer</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Glioblastoma</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-137</td><td align="left" rowspan="1" colspan="1">miR-137</td><td align="left" rowspan="1" colspan="1">MIR137HG</td><td align="left" rowspan="1" colspan="1">Exon</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Neuroblastoma</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">[<xref rid="ref82" ref-type="bibr">82</xref>, <xref rid="ref83" ref-type="bibr">83</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-139</td><td align="left" rowspan="1" colspan="1">miR-139</td><td align="left" rowspan="1" colspan="1">PDE2A</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Endometrial; colorectal cancer</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">[<xref rid="ref67" ref-type="bibr">67</xref>, <xref rid="ref84" ref-type="bibr">84</xref>, <xref rid="ref85" ref-type="bibr">85</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-149</td><td align="left" rowspan="1" colspan="1">miR-149</td><td align="left" rowspan="1" colspan="1">GPC1</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">0.37<sup>**</sup></td><td align="left" rowspan="1" colspan="1">[<xref rid="ref86" ref-type="bibr">86</xref>]</td></tr><tr><td align="left" rowspan="2" colspan="1">miR-152</td><td align="left" rowspan="2" colspan="1">miR-152</td><td align="left" rowspan="2" colspan="1">COPZ2</td><td align="left" rowspan="2" colspan="1">Intron</td><td align="left" rowspan="2" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Prostate cancer</td><td align="left" rowspan="2" colspan="1">0.31<sup>**</sup><break/>0.70<sup>**</sup></td><td align="left" rowspan="2" colspan="1">[<xref rid="ref67" ref-type="bibr">67</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Endometrial cancer</td></tr><tr><td align="left" rowspan="6" colspan="1">miR-153</td><td align="left" rowspan="3" colspan="1">miR-153-1</td><td align="left" rowspan="3" colspan="1">PTPRN</td><td align="left" rowspan="6" colspan="1">Intron</td><td align="left" rowspan="6" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Ovarian cancer</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="3" colspan="1">[<xref rid="ref87" ref-type="bibr">87</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Glioblastoma</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastric cancer</td><td align="left" rowspan="1" colspan="1">&#x02212;0.007</td></tr><tr><td align="left" rowspan="3" colspan="1">miR-153-2</td><td align="left" rowspan="3" colspan="1">PTPRN2</td><td align="left" rowspan="1" colspan="1">Ovarian cancer</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="3" colspan="1">[<xref rid="ref87" ref-type="bibr">87</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Glioblastoma</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastric cancer</td><td align="left" rowspan="1" colspan="1">0.45<sup>**</sup></td></tr><tr><td align="left" rowspan="2" colspan="1">miR-155</td><td align="left" rowspan="2" colspan="1">miR-155</td><td align="left" rowspan="2" colspan="1">MIR155HG</td><td align="left" rowspan="2" colspan="1">Exon</td><td align="left" rowspan="2" colspan="1">onco-miR</td><td align="left" rowspan="1" colspan="1">B-cell cancers</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="2" colspan="1">[<xref rid="ref88" ref-type="bibr">88&#x02013;91</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Glioblastoma</td><td align="left" rowspan="1" colspan="1">0.68<sup>**</sup></td></tr><tr><td align="left" rowspan="4" colspan="1">miR-181a</td><td align="left" rowspan="2" colspan="1">miR-181a-1</td><td align="left" rowspan="2" colspan="1">MIR181A1HG</td><td align="left" rowspan="4" colspan="1">Intron</td><td align="left" rowspan="4" colspan="1">onco-miR</td><td align="left" rowspan="1" colspan="1">Cervical cancer</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="4" colspan="1">[<xref rid="ref92" ref-type="bibr">92</xref>, <xref rid="ref93" ref-type="bibr">93</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="2" colspan="1">miR-181a-2</td><td align="left" rowspan="2" colspan="1">MIR181A2HG</td><td align="left" rowspan="1" colspan="1">Cervical cancer</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="3" colspan="1">miR-185</td><td align="left" rowspan="3" colspan="1">miR-185</td><td align="left" rowspan="3" colspan="1">TANGO2</td><td align="left" rowspan="3" colspan="1">Intron</td><td align="left" rowspan="3" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Colorectal cancer</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="3" colspan="1">[<xref rid="ref94" ref-type="bibr">94</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Lung cancer</td><td align="left" rowspan="1" colspan="1">0.49<sup>**</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">0.36<sup>**</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">miR-186</td><td align="left" rowspan="1" colspan="1">miR-186</td><td align="left" rowspan="1" colspan="1">ARANB2</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Glioblastoma</td><td align="left" rowspan="1" colspan="1">0.4<sup>**</sup></td><td align="left" rowspan="1" colspan="1">[<xref rid="ref95" ref-type="bibr">95</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-198</td><td align="left" rowspan="1" colspan="1">miR-198</td><td align="left" rowspan="1" colspan="1">FSTL1</td><td align="left" rowspan="1" colspan="1">Exon</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">&#x02212;0.04</td><td align="left" rowspan="1" colspan="1">[<xref rid="ref96" ref-type="bibr">96</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-210</td><td align="left" rowspan="1" colspan="1">miR-210</td><td align="left" rowspan="1" colspan="1">MIR210HG</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">onco-miR</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">[<xref rid="ref97" ref-type="bibr">97</xref>]</td></tr><tr><td align="left" rowspan="3" colspan="1">miR-218</td><td align="left" rowspan="2" colspan="1">miR-218-1</td><td align="left" rowspan="2" colspan="1">SLIT2</td><td align="left" rowspan="3" colspan="1">Intron</td><td align="left" rowspan="3" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">0.17<sup>**</sup></td><td align="left" rowspan="2" colspan="1">[<xref rid="ref98" ref-type="bibr">98</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastric cancer</td><td align="left" rowspan="1" colspan="1">0.66<sup>**</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">miR-218-2</td><td align="left" rowspan="1" colspan="1">SLIT3</td><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">0.33<sup>**</sup></td><td align="left" rowspan="1" colspan="1">118</td></tr><tr><td align="left" rowspan="2" colspan="1">miR-224/452</td><td align="left" rowspan="1" colspan="1">miR-224</td><td align="left" rowspan="2" colspan="1">GABRE</td><td align="left" rowspan="2" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">onco-miR</td><td align="left" rowspan="1" colspan="1">Gastric cancer; lung cancer</td><td align="left" rowspan="1" colspan="1">0.69<sup>**</sup>, 0.83<sup>**</sup><break/>0.75<sup>**</sup>, 0.80<sup>**</sup></td><td align="left" rowspan="1" colspan="1">[<xref rid="ref99" ref-type="bibr">99</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-452</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Prostate cancer</td><td align="left" rowspan="1" colspan="1">0.58<sup>**</sup>, 0.63<sup>**</sup></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">miR-326</td><td align="left" rowspan="1" colspan="1">miR-326</td><td align="left" rowspan="1" colspan="1">ARRB1</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Lung cancer</td><td align="left" rowspan="1" colspan="1">0.41<sup>**</sup></td><td align="left" rowspan="1" colspan="1">[<xref rid="ref67" ref-type="bibr">67</xref>, <xref rid="ref100" ref-type="bibr">100</xref>]</td></tr><tr><td align="left" rowspan="4" colspan="1">miR-335</td><td align="left" rowspan="4" colspan="1">miR-335</td><td align="left" rowspan="4" colspan="1">MEST</td><td align="left" rowspan="4" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">onco-miR</td><td align="left" rowspan="1" colspan="1">Ovarian cancer</td><td align="left" rowspan="1" colspan="1">0.66<sup>**</sup></td><td align="left" rowspan="1" colspan="1">[<xref rid="ref101" ref-type="bibr">101</xref>, <xref rid="ref102" ref-type="bibr">102</xref>]</td></tr><tr><td align="left" rowspan="3" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Gastric cancer</td><td align="left" rowspan="1" colspan="1">0.79<sup>**</sup></td><td align="left" rowspan="3" colspan="1">[<xref rid="ref103" ref-type="bibr">103</xref>, <xref rid="ref104" ref-type="bibr">104</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Liver cancer</td><td align="left" rowspan="1" colspan="1">0.88<sup>**</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">0.78<sup>**</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">miR-338</td><td align="left" rowspan="1" colspan="1">miR-338</td><td align="left" rowspan="1" colspan="1">AATK</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">0.61<sup>**</sup></td><td align="left" rowspan="1" colspan="1">[<xref rid="ref105" ref-type="bibr">105</xref>]</td></tr><tr><td align="left" rowspan="2" colspan="1">miR-340</td><td align="left" rowspan="2" colspan="1">miR-340</td><td align="left" rowspan="2" colspan="1">RNF130</td><td align="left" rowspan="2" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">onco-miR</td><td align="left" rowspan="1" colspan="1">Gastric cancer</td><td align="left" rowspan="1" colspan="1">0.35<sup>**</sup></td><td align="left" rowspan="1" colspan="1">[<xref rid="ref99" ref-type="bibr">99</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">0.28<sup>**</sup></td><td align="left" rowspan="1" colspan="1">[<xref rid="ref106" ref-type="bibr">106</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-342</td><td align="left" rowspan="1" colspan="1">miR-342</td><td align="left" rowspan="1" colspan="1">EVL</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Colorectal cancer</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">[<xref rid="ref107" ref-type="bibr">107</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-346</td><td align="left" rowspan="1" colspan="1">miR-346</td><td align="left" rowspan="1" colspan="1">GRID1</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Liver cancer</td><td align="left" rowspan="1" colspan="1">0.10</td><td align="left" rowspan="1" colspan="1">[<xref rid="ref108" ref-type="bibr">108</xref>]</td></tr><tr><td align="left" rowspan="2" colspan="1">miR-449a/b</td><td align="left" rowspan="1" colspan="1">miR-449a</td><td align="left" rowspan="2" colspan="1">CDC20B</td><td align="left" rowspan="2" colspan="1">Intron</td><td align="left" rowspan="2" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Neuroblastoma</td><td align="left" rowspan="1" colspan="1">0.23<sup>**</sup>, 0.61<sup>**</sup></td><td align="left" rowspan="1" colspan="1">[<xref rid="ref109" ref-type="bibr">109</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-449b</td><td align="left" rowspan="1" colspan="1">Prostate cancer</td><td align="left" rowspan="1" colspan="1">0.09, &#x02212;0.25<sup>**</sup></td><td align="left" rowspan="1" colspan="1">[<xref rid="ref110" ref-type="bibr">110</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-486</td><td align="left" rowspan="1" colspan="1">miR-486</td><td align="left" rowspan="1" colspan="1">ANK1</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Esophageal cancer</td><td align="left" rowspan="1" colspan="1">0.31<sup>**</sup></td><td align="left" rowspan="1" colspan="1">[<xref rid="ref111" ref-type="bibr">111</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-488</td><td align="left" rowspan="1" colspan="1">miR-488</td><td align="left" rowspan="1" colspan="1">ASTN1</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Gastric cancer</td><td align="left" rowspan="1" colspan="1">&#x02212;0.2<sup>*</sup></td><td align="left" rowspan="1" colspan="1">[<xref rid="ref112" ref-type="bibr">112</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-489</td><td align="left" rowspan="1" colspan="1">miR-489</td><td align="left" rowspan="1" colspan="1">CALCR</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Esophageal cancer</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">[<xref rid="ref113" ref-type="bibr">113</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-491</td><td align="left" rowspan="1" colspan="1">miR-491</td><td align="left" rowspan="1" colspan="1">FOCAD</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Colorectal cancer</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">[<xref rid="ref114" ref-type="bibr">114</xref>]</td></tr><tr><td align="left" rowspan="3" colspan="1">miR-504</td><td align="left" rowspan="3" colspan="1">miR-504</td><td align="left" rowspan="3" colspan="1">FGF13</td><td align="left" rowspan="3" colspan="1">Intron</td><td align="left" rowspan="2" colspan="1">onco-miR</td><td align="left" rowspan="1" colspan="1">HSCC</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="3" colspan="1">[<xref rid="ref115" ref-type="bibr">115&#x02013;117</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Neuroblastoma</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Glioblastoma</td><td align="left" rowspan="1" colspan="1">0.67<sup>**</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">miR-634</td><td align="left" rowspan="1" colspan="1">miR-634</td><td align="left" rowspan="1" colspan="1">PRKCA</td><td align="left" rowspan="1" colspan="1">Intron</td><td align="left" rowspan="1" colspan="1">ts-miR</td><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">[<xref rid="ref118" ref-type="bibr">118</xref>]</td></tr><tr><td align="left" rowspan="2" colspan="1">miR-1908</td><td align="left" rowspan="2" colspan="1">miR-1908</td><td align="left" rowspan="2" colspan="1">FADS1</td><td align="left" rowspan="2" colspan="1">Intron</td><td align="left" rowspan="2" colspan="1">onco-miR</td><td align="left" rowspan="1" colspan="1">Glioblastoma</td><td align="left" rowspan="1" colspan="1">&#x02212;0.12<sup>*</sup></td><td align="left" rowspan="2" colspan="1">[<xref rid="ref57" ref-type="bibr">57</xref>, <xref rid="ref58" ref-type="bibr">58</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Ovarian cancer</td><td align="left" rowspan="1" colspan="1">0.01</td></tr></tbody></table><table-wrap-foot><p>Cells with `&#x02013;&#x02019; means correlation coefficients were not available since the expression of miRNA and/or its host gene were undetected in this cancer type.</p><fn id="tblfn1"><p>
<sup>*</sup>Represents the FDR&#x000a0;&#x02264;&#x000a0;0.01.</p></fn><fn id="tblfn2"><p>
<sup>**</sup>Represents the FDR&#x000a0;&#x02264;&#x000a0;0.001.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec5"><title>Association between intragenic onco/ts-miRNAs and their host genes in cancer</title><p>Disruption of miRNA expression is frequently observed in cancer. They can act as oncogenes and/or tumor suppressors. Study of a large collection of chronic lymphocytic leukemias (CLLs) showed knockdown or knock out of miR-15a and miR-16-1 in approximately 69% of CLLs. This is the first evidence that miRNAs might be involved in the pathogenesis of human cancer [<xref rid="ref6" ref-type="bibr">6</xref>]. Frixa <italic>et al</italic>. [<xref rid="ref45" ref-type="bibr">45</xref>] reported that miR-128-3p, upregulated in lung cancer, targets Drosha and Dicer, two key enzymes of miRNAs processing, leading to the widespread down-regulation of miRNA expression that promotes lung cancer cell migration [<xref rid="ref46" ref-type="bibr">46</xref>]. The capability of targeting a number of genes with diverse functions makes miRNAs ideal candidates to regulate core carcinogenesis process [<xref rid="ref47" ref-type="bibr">47&#x02013;50</xref>].</p><p>Most onco-miRs or ts-miRs are intragenic miRNAs. Increasing evidences demonstrated links between intragenic miRNAs and host genes in cancer. They act in synergistic or antagonistic ways, which is achieved by miRNA-mediated fine-tuning target gene expression functionally related to host genes [<xref rid="ref51" ref-type="bibr">51</xref>]. Due to the close functional connection between intragenic miRNAs and host genes, it is necessary and important to interpret the function of these onco-miRs and ts-miRs in the context of host genes. TCGA provides a rich source of multi-dimensional omics data, which gives a unique opportunity to study the expression of intragenic miRNAs and their host genes simultaneously across multiple cancer types. A positively correlated expression patterns would indicate a co-regulation and/or synergistic relationship between host and intragenic miRNAs, while anti-correlated or uncorrelated expression patterns would suggest an independent or antagonistic process.</p><p>Known onco-miRs and ts-miRs, specific cancer(s) where they are involved in, their cognate host genes and their expression correlation coefficients in specific cancer(s) are listed in <xref rid="TB1" ref-type="table">Table 1</xref>. Most intragenic onco-miRs and ts-miRs are embedded within intron regions of genes. They exhibited a strong co-expression relationship with their cognate host genes, suggesting co-transcription and/or potential cooperation in regulating cancer development. The results derived from TCGA data sets further validated previous findings. For example, miR-335 harbored within an intron of a protein-coding gene <italic>MEST</italic>, was known to be co-regulated with <italic>MEST</italic> by promoter hypermethylation in breast cancer cells [<xref rid="ref119" ref-type="bibr">119</xref>], HCC [<xref rid="ref29" ref-type="bibr">29</xref>] and gastric cancer [<xref rid="ref120" ref-type="bibr">120</xref>]. Consistently, the expression of miR-335 and <italic>MEST</italic> are highly correlated in TCGA HCC (R&#x000a0;=&#x000a0;0.88; FDR&#x000a0;=&#x000a0;9.87e-05), breast (R&#x000a0;=&#x000a0;0.78; FDR&#x000a0;=&#x000a0;0) and gastric cancer (R&#x000a0;=&#x000a0;0.79; FDR&#x000a0;=&#x000a0;0), further validating of the co-regulation relationship between miR-335 and <italic>MEST</italic> is needed. MiR-106b-25 cluster, composed of the highly conserved miR-106b, miR-93 and miR-25, is embedded within an intron 13 of <italic>MCM7</italic>. Petrocca <italic>et al</italic>. [<xref rid="ref121" ref-type="bibr">121</xref>] reported that the <italic>MCM7</italic> and miR-106b-25 cooperate in exerting their oncogenic function through different complementary mechanisms. Consistently, miR-106b-25 and <italic>MCM7</italic> are highly co-expressed in TCGA breast cancer (R&#x000a0;=&#x000a0;0.68, 0.57, 0.66; FDR&#x000a0;=&#x000a0;0, 0, 0), further demonstrating that they are derived from the same primary transcript. Meanwhile, intronic miR-224/452 cluster showed significant co-expression with their host gene <italic>GABRE</italic> in prostate cancer (R&#x000a0;=&#x000a0;0.58, 0.63; FDR&#x000a0;=&#x000a0;0, 0) [<xref rid="ref122" ref-type="bibr">122</xref>].</p><fig id="f3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Scatter plot of expression abundance of miR-21 and its host gene VMP1 in multiple cancers.</p></caption><graphic xlink:href="elz002f3"/></fig><fig id="f4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Scatter plot of expression abundance of miR-338 and its host gene AATK in ER/PR/HER2-positive and triple-negative breast cancers.</p></caption><graphic xlink:href="elz002f4"/></fig><p>Although most intronic onco/ts-miRs are co-expressed with their host genes in cancers, there are some exceptions. For example, expression of miR-30c-1 is not correlated with its host gene <italic>NFYC</italic> (R&#x000a0;=&#x000a0;0.06; FDR&#x000a0;=&#x000a0;0.23) in prostate cancer, suggesting that it does not originate from the <italic>NFYC</italic> transcription unit. Several cryptic promoters and possible transcription factor binding sites have been detected in the intron regions of <italic>NFYC</italic> where miR-30c-1 is located, indicating miR-30c-1 is transcribed independent from <italic>NFYC</italic> [<xref rid="ref123" ref-type="bibr">123</xref>]. Consistent with previous findings that miR-1908 is regulated by its own transcription unit rather than co-regulated with its host gene <italic>FADS1</italic> [<xref rid="ref34" ref-type="bibr">34</xref>], we found that expressions of miR-1908 and <italic>FADS1</italic> are negatively correlated/uncorrelated in glioblastoma and ovarian cancer (R&#x000a0;=&#x000a0;&#x02212;0.12, 0.01; FDR&#x000a0;=&#x000a0;0.01, 0.87). In addition to known independent transcriptional relationships, TCGA data sets revealed novel uncorrelated/negatively correlated patterns between some intronic miRNAs and their host genes&#x02014;for example, miR-346 and <italic>GRID1</italic> in liver cancer (R&#x000a0;=&#x000a0;0.1; FDR&#x000a0;=&#x000a0;0.81), miR-488 and <italic>ASTN1</italic> in gastric cancer (R&#x000a0;=&#x000a0;&#x02212;0.2; FDR&#x000a0;=&#x000a0;0.006) and miR-489 and <italic>CALCR</italic> in esophageal cancer (R&#x000a0;=&#x000a0;0.02; FDR&#x000a0;=&#x000a0;0.72). The uncorrelated/negative correlation indicated these miRNAs might have their own transcription mechanism rather than share the promoter as their host genes.</p><p>There are three onco/ts-miRs harbored within exonic regions, miR-137, miR-155 and miR-198. MiR-198 is located in the 3&#x02032;-UTR region of protein-coding gene <italic>FSTL1</italic>, while the other two miRNAs are encoded in the exon of non-coding genes, <italic>MIR137HG</italic> and <italic>MIR155HG</italic>. MiR-198 is not co-expressed with its host gene <italic>FSTL1</italic> (R&#x000a0;=&#x000a0;&#x02212;0.04 in breast cancer; FDR&#x000a0;=&#x000a0;0.52), which validates previous finding about their mutually exclusive expression from a single transcript [<xref rid="ref37" ref-type="bibr">37</xref>]. In contrast, miR-155 is co-transcribed with <italic>MIR155HG</italic> possibly because the gene itself is to generate the miRNA rather than produce other functional unit, leading to the high co-expression pattern in glioblastoma (R&#x000a0;=&#x000a0;0.68; FDR&#x000a0;=&#x000a0;0).</p><p>MiR-21, involved in many cancers, has been reported to be a readthrough miRNA from <italic>VMP1</italic>. The host gene, <italic>VMP1</italic>, was recently found to be involved in the process of tumor metastasis and it plays a vital role in balancing apoptosis and autophagy [<xref rid="ref38" ref-type="bibr">38</xref>, <xref rid="ref124" ref-type="bibr">124</xref>]. miR-21 and <italic>VMP1</italic> are co-expressed across multiple cancer types (R&#x000a0;=&#x000a0;0.52, 0.36, 0.61, 0.39; FDR&#x000a0;=&#x000a0;0, 0.003, 0, 4.18e-12, in breast, lung, pancreas, and cervical cancers, respectively) (<xref rid="f3" ref-type="fig">Figure 3</xref>). These findings further validated that miR-21 is the byproduct of transcription of <italic>VMP1</italic>.</p><p>MiR-34b and BTG4 are co-regulated by a bidirectional promoter [<xref rid="ref40" ref-type="bibr">40</xref>]. It has been revealed that miR-34b has tumor suppressive ability in breast and prostate cancer [<xref rid="ref73" ref-type="bibr">73</xref>]. However, TCGA data indicated that there is no correlation between expression of miR-34b and BTG4. Further research is needed to investigate whether this is caused by independent transcription or whether the co-transcription is disrupted by regulation feed-back between miRNAs and host genes.</p><p>Most interestingly, 15 out of 46 miRNA clusters show cancer-specific co-expression patterns with their host genes, suggesting the common involvement of cancer-specific post-transcription regulation&#x02014;for example, miR-17-92 cluster, encoded the miR-17, miR-18a, miR-19a/b1, miR-20a and miR-92a1. miR-17-92 cluster, regarded as oncogene, was frequently overexpressed in lymphomas, lung cancer and renal cancer [<xref rid="ref57" ref-type="bibr">57&#x02013;59</xref>]. All miRNAs in the cluster showed strong correlation with the host gene C13orf25 in lung cancer (R&#x000a0;=&#x000a0;0.49, 0.48, 0.58, 0.55, 0.48, 0.51; FDR&#x000a0;=&#x000a0;2.26e-5, 2.89e-5, 1.35e-7, 1.08e-6, 2.82e-5, 9.90e-6), but weak/discordant correlation in renal cell cancer (R&#x000a0;=&#x000a0;0.07, 0.01, 0.11, 0.07, 0.16, 0.19; FDR&#x000a0;=&#x000a0;0.47, 0.93, 0.22, 0.47, 0.06, 0.02). These results suggest that miRNAs and host genes are co-transcribed from one transcript but renal cancer-specific post-transcription interferes the co-transcriptional regulation. In addition to cancer-specific pattern, some miRNAs even exhibit subtype-specific co-expression with their host genes in one cancer. For example, miR-338 is strongly co-expressed with its host gene AATK in ER/PR/HER2-positive breast cancers (R&#x000a0;=&#x000a0;0.63, 0.65, 0.63; FDR&#x000a0;=&#x000a0;0, 0, 2.49e-7), but this positive correlation is lost in triple-negative breast cancer (R&#x000a0;=&#x000a0;&#x02212;0.27, FDR&#x000a0;=&#x000a0;0.07) (<xref rid="f4" ref-type="fig">Figure 4</xref>).</p></sec><sec id="sec6"><title>Potential as the therapeutic targets in cancer</title><p>As master regulators of cellular processes, miRNAs have become promising therapeutic targets for cancer treatment. Upregulation of the expression of a ts-miR can induce apoptosis and senescence, block cell proliferation, self-renewal, invasion, metastasis, angiogenesis and drug resistance by selectively downregulating multiple genes [<xref rid="ref125" ref-type="bibr">125</xref>]. Conversely, inhibiting the function or blocking the expression of an onco-miR in cancer cells can reactivate multiple tumor-suppressor genes, leading to tumor regression or even to tumor eradication [<xref rid="ref126" ref-type="bibr">126</xref>].</p><p>Since most onco-miRs or ts-miRs are intragenic miRNAs, the observation that they are often co-expressed with host genes (<xref rid="TB1" ref-type="table">Table 1</xref>), provides a new strategy to regulate miRNAs expression for cancer therapy. When miRNAs are derived from the transcription of host genes rather than have their own independent promoters, disruption of the expression of host genes or especially epigenetic modification of promoters of host genes is highly likely to change the miRNA expression. For example, miR-335, known to suppress breast cancer cell migration, is highly co-expressed with its host gene in breast cancer (<xref rid="TB1" ref-type="table">Table 1</xref>). Furthermore, miR-335 expression is significantly negatively correlated with the MEST promoter DNA methylation level (R&#x000a0;=&#x000a0;&#x02212;0.32; <italic>P</italic>&#x000a0;=&#x000a0;0.0002), suggesting that promoter DNA demethylation would activate miR-335.</p><p>Since epigenetic modification is potentially reversible, it has been aggressively pursued as therapeutic strategy. Grady <italic>et al</italic>. [<xref rid="ref107" ref-type="bibr">107</xref>] showed that there is synchronous epigenetic silencing of the intronic ts-miR miR-342 and its host gene <italic>EVL</italic> in colorectal cancer. Reconstitution of miR-342 activity induces apoptosis in colorectal cancer cells. Daniunaite <italic>et al</italic>. [<xref rid="ref127" ref-type="bibr">127</xref>] analyzed the promoter methylation level of host genes of miR-155, miR-152, miR-137 and miR-31 in prostate cancer. They found that aberrant promoter methylation of the host genes is prostate cancer-specific. Downregulation of miR-155-5p significantly correlates with the promoter methylation level, which can be used as the promising diagnostic and/or prognostic biomarker of prostate cancer. The methylation status of host genes of particular miRNA as independent variables or in combinations with other signals might assist physicians in identifying prostate cancer patients with poor prognosis preoperatively. Besides, miR-152 and <italic>COPZ2</italic> were both silenced by hypermethylation in endometrial cancer. They are highly co-expressed in TCGA endometrial cancer data (R&#x000a0;=&#x000a0;0.70; FDR&#x000a0;=&#x000a0;0; <xref rid="TB1" ref-type="table">Table 1</xref>). Tsuruta <italic>et al</italic>. [<xref rid="ref67" ref-type="bibr">67</xref>] investigated the relationship between DNA hypermethylation and downregulation of miR-152 and <italic>COPZ2</italic> expression. They found that DNA hypermethylation-mediated silencing of miR-152 and <italic>COPZ2</italic> was a relatively frequent molecular event in endometrial cancer and inhibited cell growth in endometrial cancer cell lines, suggesting the epigenetic silencing of these genes to contribute to endometrial carcinogenesis. The restoration of miR-152 expression in endometrial cancer cell lines was sufficient to inhibit tumor cell growth in vitro and in vivo.</p><p>For the specific miRNA with dual identity that either onco-miR or ts-miR, there are different methylation pattern in different cancers. miR-224 and miR-452 are located in the intron 6 of the host gene &#x003b3;-aminobutyric acid A receptor (<italic>GABRE</italic>). There are significant positive correlations between expressions of miR-224, miR-452 and <italic>GABRE</italic> in previous studies [<xref rid="ref122" ref-type="bibr">122</xref>] and TCGA data sets across cancer types (R&#x000a0;=&#x000a0;0.58~0.83; FDR&#x000a0;=&#x000a0;0; <xref rid="TB1" ref-type="table">Table 1</xref>), demonstrating that these three genes are transcriptionally co-regulated under the same promoter. Cui <italic>et al</italic>. [<xref rid="ref128" ref-type="bibr">128</xref>] found that miR-224 was significantly upregulated and the CpG island in the promoter region of miR-224 was hypomethylated in lung cancer, suggesting the potent oncogenic role in lung cancer. In contrast, GABRE~miR-452~miR-224 locus is downregulated and hypermethylated in prostate cancer, suggesting tumor-suppressive role in prostate cancer [<xref rid="ref122" ref-type="bibr">122</xref>]. Silencing/activating these miRNAs by epigenetic alterations of cognate host genes can be a potential way for cancer therapy.</p><p>Besides DNA methylation, histone acetylation is another way of epigenetic regulation. The ts-miRs of miR-15a/16&#x02013;1, encoded within an intron region of the non-coding <italic>DLEU2</italic> gene, are downregulated in multiple tumor types while being frequently deleted in CLL. miR-15a/16&#x02013;1 is believed to be transcribed from the <italic>DLEU2</italic> promoter. Kasar <italic>et al</italic>. [<xref rid="ref129" ref-type="bibr">129</xref>] revealed that the transcription factor <italic>BSAP</italic> (B-cell-specific activator protein) directly interacts with <italic>DLEU2</italic>, resulting in repression of miR-15a/16&#x02013;1 expression by negative regulation of the <italic>DLEU2</italic> promoter. Derepression of the <italic>DLEU2</italic> promoter via inhibition of histone deacetylation in combination with <italic>BSAP</italic> knockdown increased miR-15a/16&#x02013;1 expression, leading to malignant B-cell death. Thus, therapy targeting enhanced host gene <italic>DLEU2</italic> transcription may augment CLL therapy. miR-126, harbored within the intron of the <italic>EGFL7</italic> gene, is downregulated in cancer cell lines and also in primary bladder and prostate tumors. miR-126 and one of the transcripts of <italic>EGFL7</italic> are concomitantly upregulated in cancer cell lines by inhibitors of DNA methylation and histone deacetylation. All these findings demonstrated that epigenetic changes can control the expression of onco/ts-miRs by directly controlling their host genes [<xref rid="ref130" ref-type="bibr">130</xref>]. The knowledge of common and cancer-specific co-transcription patterns between miRNAs and host genes will help design therapeutic methods, targeting miRNA expression efficiently.</p><p>The advantage of miRNAs as therapeutic agents is based on their ability to concurrently target a large number of genes/pathways. However, this ability also causes a major concern on their toxicity due to potential off-target effects. While miRNAs target oncogenic pathways, they modulate other biological processes, which would cause far stronger side effects than generally appreciated [<xref rid="ref131" ref-type="bibr">131</xref>]. Additionally, most existing strategies only focus on single miRNA or a family of miRNAs. Since miRNAs act cooperatively in tumor initiation and progression, modulating single miRNA expression has a limited effect. Tumor proliferation can be easily restored through bypassing the miRNA. Strategies to reprogram aberrant miRNA networks in cancer would be more effective [<xref rid="ref132" ref-type="bibr">132</xref>]. Other challenges for developing miRNA therapeutics include low bioavailability, limited effective delivery and long-term safety [<xref rid="ref133" ref-type="bibr">133</xref>].</p></sec></sec><sec id="sec7"><title>Conclusion</title><p>Dysregulation of miRNAs expression plays a critical role in human diseases, especially in cancer. There is a close functional connection and complicated interplay between miRNAs and host genes; therefore, it is essential to study the miRNA regulation in the context of their cognate host genes. Since most onco/ts-miRs are intragenic miRNAs, we studied the co-expression relationship between these miRNAs and host genes based on TCGA data sets. The common and cancer-specific co-expression relationships will facilitate the design of therapeutic methods to silence/activate onco/ts-miRs efficiently by epigenetic alterations of cognate host genes.</p><boxed-text id="box01" position="float" orientation="portrait"><sec id="sec9"><title>Key Points</title><p>
<list list-type="bullet"><list-item><p>Although there is a general understanding of the generation of mature miRNA from primary miRNA, the transcriptional regulation of primary miRNAs is still unclear.</p></list-item><list-item><p>Recent studies have shown that more than half of miRNAs are located within protein-coding or non-coding genes. Intragenic miRNAs and their host genes either share the promoter or have independent
transcription.</p></list-item><list-item><p>Most ts-miRs and onco-miRs are intragenic miRNAs; therefore, it is necessary and important to interpret their function in the context of host genes.</p></list-item><list-item><p>The knowledge of common and tumor-specific co-expression patterns between miRNAs and host genes is very helpful for understanding transcriptional and post-transcriptional regulation of miRNAs and further developing miRNA therapeutics in cancer.</p></list-item></list>
</p></sec></boxed-text></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sup1"><label>point_to_point_response_1122_Supp_elz002</label><media xlink:href="point_to_point_response_1122_supp_elz002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><sec><title>Funding</title><p>This work was supported by the Innovative Special Project of Agricultural Sci-Tech (Grant No. CAASASTIP-2014-LVRI-09).</p></sec><notes id="bio3"><sec sec-type="author-bio" id="sec10"><title/><p>
<bold>Baohong Liu</bold> got her PhD in bioinformatics from Tongji University in 2011 and worked in State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Parasitology of Gansu Province,
Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences from 2014. In 2017&#x02013;18, she was a visiting scholar in Vanderbilt University.</p><p>
<bold>Yu Shyr</bold> received his PhD in biostatistics from the University of Michigan in 1994. Now he is the Chair of Department of Biostatistics in Vanderbilt University.</p><p>
<bold>Jianping Cai</bold> is the director of the laboratory of poultry research in State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Parasitology of Gansu Province, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences.
He is interested in the study of the genome, protein function for chicken parasites.</p><p>
<bold>Qi Liu</bold> received her PhD at Shanghai Jiaotong University in 2003, completed her postdoc at Vanderbilt University and is now the assistant professor in Vanderbilt University.</p></sec></notes><ref-list id="bib1"><title>Reference</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bartel</surname><given-names>DP</given-names></name></person-group>
<article-title>MicroRNAs: target recognition and regulatory functions</article-title>. <source>Cell</source><year>2009</year>;<volume>136</volume>(<issue>2</issue>):<fpage>215</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">19167326</pub-id></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nozawa</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Miura</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Nei</surname><given-names>M</given-names></name></person-group>
<article-title>Origins and evolution of microRNA genes in plant species</article-title>. <source>Genome Biol Evol</source><year>2012</year>;<volume>4</volume>(<issue>3</issue>):<fpage>230</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22223755</pub-id></mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ohtsuka</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ling</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Doki</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MicroRNA processing and human cancer</article-title>. <source>J Clin Med</source><year>2015</year>;<volume>4</volume>(<issue>8</issue>):<fpage>1651</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">26308063</pub-id></mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Perron</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Provost</surname><given-names>P</given-names></name></person-group>
<article-title>Protein interactions and complexes in human microRNA biogenesis and function</article-title>. <source>Front Biosci</source><year>2008</year>;<volume>13</volume>:<fpage>2537</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">17981733</pub-id></mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bartel</surname><given-names>DP</given-names></name></person-group>
<article-title>MicroRNAs: genomics, biogenesis, mechanism, and function</article-title>. <source>Cell</source><year>2004</year>;<volume>116</volume>(<issue>2</issue>):<fpage>281</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">14744438</pub-id></mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Calin</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>Dumitru</surname><given-names>CD</given-names></name>, <name name-style="western"><surname>Shimizu</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2002</year>;<volume>99</volume>(<issue>24</issue>):<fpage>15524</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">12434020</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Oliveto</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mancino</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Manfrini</surname><given-names>N</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Role of microRNAs in translation regulation and cancer</article-title>. <source>World J Biol Chem</source><year>2017</year>;<volume>8</volume>(<issue>1</issue>):<fpage>45</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">28289518</pub-id></mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Matyunina</surname><given-names>LV</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>LD</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Evidence for the importance of post-transcriptional regulatory changes in ovarian cancer progression and the contribution of miRNAs</article-title>. <source>Sci Rep</source><year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>8171</fpage>.<pub-id pub-id-type="pmid">28811560</pub-id></mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jing</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>W</given-names></name>, <etal>et al.</etal></person-group>
<article-title>CRISPR/CAS9-mediated genome editing of miRNA-155 inhibits proinflammatory cytokine production by RAW264.7 cells</article-title>. <source>Biomed Res Int</source><year>2015</year>;<volume>2015</volume>:<fpage>1</fpage>&#x02013;<lpage>7</lpage>,<comment>326042</comment>.</mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Huo</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Yin</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Lentiviral CRISPR/Cas9
vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells</article-title>. <source>J Cancer</source><year>2017</year>;<volume>8</volume>(<issue>1</issue>):<fpage>57</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">28123598</pub-id></mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>P</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Young intragenic miRNAs are less coexpressed with host genes than old ones: implications of miRNA-host gene coevolution</article-title>. <source>Nucleic Acids Res</source><year>2012</year>;<volume>40</volume>(<issue>9</issue>):<fpage>4002</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">22238379</pub-id></mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Qiao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>D</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Enemy or partner: relationship between intronic micrornas and their host genes</article-title>. <source>IUBMB Life</source><year>2012</year>;<volume>64</volume>(<issue>10</issue>):<fpage>835</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">22941954</pub-id></mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Qiao</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Coexpression of an intronic microRNA and its host gene reveals a potential role for miR-483-5p as an IGF2 partner</article-title>. <source>Mol Cell Endocrinol</source><year>2011</year>;<volume>333</volume>(<issue>1</issue>):<fpage>96</fpage>&#x02013;<lpage>101</lpage>.<pub-id pub-id-type="pmid">21146586</pub-id></mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Qian</surname><given-names>W</given-names></name>, <etal>et al.</etal></person-group>
<article-title>CCAR1 5' UTR as a natural miRancer of miR-1254 overrides tamoxifen resistance</article-title>. <source>Cell Res</source><year>2016</year>;<volume>26</volume>(<issue>6</issue>):<fpage>655</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">27002217</pub-id></mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hinske</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Galante</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Kuo</surname><given-names>WP</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A potential role for intragenic miRNAs on their hosts' interactome</article-title>. <source>BMC Genomics</source><year>2010</year>;<volume>11</volume>:<fpage>533</fpage>.<pub-id pub-id-type="pmid">20920310</pub-id></mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Georgakilas</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Vlachos</surname><given-names>IS</given-names></name>, <name name-style="western"><surname>Paraskevopoulou</surname><given-names>MD</given-names></name>, <etal>et al.</etal></person-group>
<article-title>microTSS: accurate microRNA transcription start site identification reveals a significant number of divergent
pri-miRNAs</article-title>. <source>Nat Commun</source><year>2014</year>;<volume>5</volume>:<fpage>5700</fpage>.<pub-id pub-id-type="pmid">25492647</pub-id></mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Seila</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Calabrese</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Levine</surname><given-names>SS</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Divergent transcription from active promoters</article-title>. <source>Science</source><year>2008</year>;<volume>322</volume>(<issue>5909</issue>):<fpage>1849</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">19056940</pub-id></mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Seila</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Core</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Lis</surname><given-names>JT</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Divergent transcription: a new feature of active promoters</article-title>. <source>Cell Cycle</source><year>2009</year>;<volume>8</volume>(<issue>16</issue>):<fpage>2557</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">19597342</pub-id></mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hinske</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Franca</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Torres</surname><given-names>HA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>miRIAD-integrating microRNA inter- and intragenic data</article-title>. <source>Database (Oxford)</source><year>2014</year>;<volume>2014</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lutter</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Marr</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Krumsiek</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Intronic microRNAs support their host genes by mediating synergistic and antagonistic regulatory effects</article-title>. <source>BMC Genomics</source><year>2010</year>;<volume>11</volume>:<fpage>224</fpage>.<pub-id pub-id-type="pmid">20370903</pub-id></mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kozomara</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Griffiths-Jones</surname><given-names>S</given-names></name></person-group>
<article-title>miRBase: annotating high confidence microRNAs using deep sequencing data</article-title>. <source>Nucleic Acids Res</source><year>2014</year>;<volume>42</volume>(<issue>Database issue</issue>):<fpage>D68</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">24275495</pub-id></mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kozomara</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Griffiths-Jones</surname><given-names>S</given-names></name></person-group>
<article-title>miRBase: integrating microRNA annotation and deep-sequencing data</article-title>. <source>Nucleic Acids Res</source><year>2011</year>;<volume>39</volume>(<issue>Database issue</issue>):<fpage>D152</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">21037258</pub-id></mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Griffiths-Jones</surname><given-names>S</given-names></name></person-group>
<article-title>miRBase: microRNA sequences and annotation</article-title>. <source>Curr Protoc Bioinformatics</source><year>2010</year>;<comment>Chapter 12, Unit 12.9</comment>;<fpage>1</fpage>&#x02013;<lpage>10</lpage>.</mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Griffiths-Jones</surname><given-names>S</given-names></name></person-group>
<article-title>miRBase: the microRNA sequence database</article-title>. <source>Methods Mol Biol</source><year>2006</year>;<volume>342</volume>:<fpage>129</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">16957372</pub-id></mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Griffiths-Jones</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Saini</surname><given-names>HK</given-names></name>, <name name-style="western"><surname>Van Dongen</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>, <article-title>miRBase: tools for microRNA genomics</article-title>. <source>Nucleic Acids Res</source><year>2008</year>;<volume>36</volume>(<issue>Database issue</issue>):<fpage>D154</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">17991681</pub-id></mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Baskerville</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bartel</surname><given-names>DP</given-names></name></person-group>
<article-title>Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes</article-title>. <source>RNA</source><year>2005</year>;<volume>11</volume>(<issue>3</issue>):<fpage>241</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15701730</pub-id></mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>YK</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>VN</given-names></name></person-group>
<article-title>Processing of intronic microRNAs</article-title>. <source>EMBO J</source><year>2007</year>;<volume>26</volume>(<issue>3</issue>):<fpage>775</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">17255951</pub-id></mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Corcoran</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Pandit</surname><given-names>KV</given-names></name>, <name name-style="western"><surname>Gordon</surname><given-names>B</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Features of mammalian microRNA promoters emerge from polymerase II chromatin immunoprecipitation data</article-title>. <source>PLoS One</source><year>2009</year>;<volume>4</volume>(<issue>4</issue>):<fpage>1</fpage>&#x02013;<lpage>10</lpage>,<comment>e5279</comment>.</mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Dohi</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Yasui</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Gen</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma</article-title>. <source>Int J Oncol</source><year>2013</year>;<volume>42</volume>(<issue>2</issue>):<fpage>411</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">23229728</pub-id></mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Barron</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Sanchez</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Sanchez</surname><given-names>P</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MicroRNAs: tiny targets for engineering CHO cell phenotypes?</article-title>
<source>Biotechnol Lett</source>
<year>2011</year>;<volume>33</volume>(<issue>1</issue>):<fpage>11</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">20872159</pub-id></mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ji</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Kumar</surname><given-names>MR</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Transcriptome integration analysis in hepatocellular carcinoma reveals discordant intronic miRNA-host gene pairs in expression</article-title>. <source>Int J Biol Sci</source><year>2017</year>;<volume>13</volume>(<issue>11</issue>):<fpage>1438</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">29209147</pub-id></mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>WC</given-names></name></person-group>
<article-title>Intronic microRNA: discovery and biological implications</article-title>. <source>DNA Cell Biol</source><year>2007</year>;<volume>26</volume>(<issue>4</issue>):<fpage>195</fpage>&#x02013;<lpage>207</lpage>.<pub-id pub-id-type="pmid">17465886</pub-id></mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Schanen</surname><given-names>BC</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name></person-group>
<article-title>Transcriptional regulation of mammalian miRNA genes</article-title>. <source>Genomics</source><year>2011</year>;<volume>97</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">20977933</pub-id></mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>HR</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>H</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MicroRNA-1908-5p contributes to the oncogenic function of the splicing factor SRSF3</article-title>. <source>Oncotarget</source><year>2017</year>;<volume>8</volume>(<issue>5</issue>):<fpage>8342</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">28039456</pub-id></mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ozsolak</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Poling</surname><given-names>LL</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Chromatin structure analyses identify miRNA promoters</article-title>. <source>Genes Dev</source><year>2008</year>;<volume>22</volume>(<issue>22</issue>): <fpage>3172</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">19056895</pub-id></mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Agranat-Tamir</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Shomron</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Sperling</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Interplay between pre-mRNA splicing and microRNA biogenesis within the supraspliceosome</article-title>. <source>Nucleic Acids Res</source><year>2014</year>;<volume>42</volume>(<issue>7</issue>):<fpage>4640</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">24464992</pub-id></mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sundaram</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Common</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Gopal</surname><given-names>FE</given-names></name>, <etal>et al.</etal></person-group>
<article-title>&#x02018;See-saw&#x02019; expression of microRNA-198 and FSTL1 from a single transcript in wound healing</article-title>. <source>Nature</source><year>2013</year>;<volume>495</volume>(<issue>7439</issue>):<fpage>103</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">23395958</pub-id></mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ribas</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ni</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Castanares</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A novel source for miR-21 expression through the alternative polyadenylation of VMP1 gene transcripts</article-title>. <source>Nucleic Acids Res</source><year>2012</year>;<volume>40</volume>(<issue>14</issue>):<fpage>6821</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">22505577</pub-id></mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Melamed</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Levy</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ashwal-Fluss</surname><given-names>R</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Alternative splicing regulates biogenesis of miRNAs located across exon-intron junctions</article-title>. <source>Mol Cell</source><year>2013</year>;<volume>50</volume>(<issue>6</issue>):<fpage>869</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">23747012</pub-id></mixed-citation></ref><ref id="ref40"><label>40.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Toyota</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Suzuki</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sasaki</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer</article-title>. <source>Cancer Res</source><year>2008</year>;<volume>68</volume>(<issue>11</issue>):<fpage>4123</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">18519671</pub-id></mixed-citation></ref><ref id="ref41"><label>41.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Saetrom</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Snove</surname><given-names>O</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MicroRNA-directed transcriptional gene silencing in mammalian cells</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2008</year>;<volume>105</volume>(<issue>42</issue>):<fpage>16230</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">18852463</pub-id></mixed-citation></ref><ref id="ref42"><label>42.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kos</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Olde Loohuis</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Wieczorek</surname><given-names>ML</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A potential regulatory role for intronic microRNA-338-3p for its host gene encoding apoptosis-associated tyrosine kinase</article-title>. <source>PLoS One</source><year>2012</year>;<volume>7</volume>(<issue>2</issue>):<comment>e31022</comment>.</mixed-citation></ref><ref id="ref43"><label>43.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Dill</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Linder</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Fehr</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Intronic miR-26b controls neuronal differentiation by repressing its host transcript, ctdsp2</article-title>. <source>Genes Dev</source><year>2012</year>;<volume>26</volume>(<issue>1</issue>):<fpage>25</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">22215807</pub-id></mixed-citation></ref><ref id="ref44"><label>44.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Schmitt</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>M</given-names></name></person-group>
<article-title>The enemy within: regulation of host genes by intronic microRNAs</article-title>. <source>Chemotherapy</source>, <year>2014</year>
<volume>3</volume>(<issue>e126</issue>):<fpage>1</fpage>&#x02013;<lpage>2</lpage>.</mixed-citation></ref><ref id="ref45"><label>45.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Frixa</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Sacconi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cioce</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MicroRNA-128-3p-mediated depletion of Drosha promotes lung cancer cell migration</article-title>. <source>Carcinogenesis</source><year>2018</year>;<volume>39</volume>(<issue>2</issue>):<fpage>293</fpage>&#x02013;<lpage>304</lpage>.<pub-id pub-id-type="pmid">29236960</pub-id></mixed-citation></ref><ref id="ref46"><label>46.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bi</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>Z</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MicroRNA-10a/b are regulators of myeloid differentiation and acute myeloid leukemia</article-title>. <source>Oncol Lett</source><year>2018</year>;<volume>15</volume>(<issue>4</issue>):<fpage>5611</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">29552198</pub-id></mixed-citation></ref><ref id="ref47"><label>47.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Cobb</surname><given-names>GP</given-names></name>, <etal>et al</etal></person-group>
<article-title>microRNAs as oncogenes and tumor suppressors</article-title>. <source>Dev Biol</source>, <year>2007</year>
<volume>302</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">16989803</pub-id></mixed-citation></ref><ref id="ref48"><label>48.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Palma Flores</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Garcia-Vazquez</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Gallardo Rincon</surname><given-names>D</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MicroRNAs driving invasion and metastasis in ovarian cancer: opportunities for translational medicine (Review)</article-title>. <source>Int J Oncol</source><year>2017</year>;<volume>50</volume>(<issue>5</issue>):<fpage>1461</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">28393213</pub-id></mixed-citation></ref><ref id="ref49"><label>49.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name></person-group>
<article-title>MicroRNA-30a-5p suppresses epithelial-mesenchymal transition by targeting profilin-2 in high invasive non-small cell lung cancer cell lines</article-title>. <source>Oncol Rep</source><year>2017</year>;<volume>37</volume>(<issue>5</issue>):<fpage>3146</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">28405690</pub-id></mixed-citation></ref><ref id="ref50"><label>50.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Byrom</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Shelton</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis</article-title>. <source>Nucleic Acids Res</source><year>2005</year>
<volume>33</volume>(<issue>4</issue>):<fpage>1290</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15741182</pub-id></mixed-citation></ref><ref id="ref51"><label>51.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hinske</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Heyn</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Galante</surname><given-names>PA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Setting up an intronic miRNA database</article-title>. <source>Methods Mol Biol</source><year>2013</year>;<volume>936</volume>:<fpage>69</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">23007499</pub-id></mixed-citation></ref><ref id="ref52"><label>52.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Leone</surname><given-names>V</given-names></name>, <name name-style="western"><surname>D'angelo</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Rubio</surname><given-names>I</given-names></name>, <etal>et al</etal></person-group>
<article-title>MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1alpha</article-title>. <source>J Clin Endocrinol Metab</source><year>2011</year>;<volume>96</volume>(<issue>9</issue>):<fpage>E1388</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="pmid">21752897</pub-id></mixed-citation></ref><ref id="ref53"><label>53.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Letelier</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Garcia</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Leal</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group>
<article-title>miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer</article-title>. <source>Int J Clin Exp Pathol</source><year>2014</year>;<volume>7</volume>(<issue>5</issue>):<fpage>1849</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">24966896</pub-id></mixed-citation></ref><ref id="ref54"><label>54.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker</article-title>. <source>Nat Med</source><year>2012</year>;<volume>18</volume>(<issue>10</issue>):<fpage>1511</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">23001183</pub-id></mixed-citation></ref><ref id="ref55"><label>55.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Young</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Prabhala</surname><given-names>H</given-names></name>, <etal>et al.</etal></person-group>
<article-title>miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis</article-title>. <source>Nat Cell Biol</source><year>2010</year>;<volume>12</volume>(<issue>3</issue>):<fpage>247</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">20173740</pub-id></mixed-citation></ref><ref id="ref56"><label>56.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Xiang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Transcriptome profiling reveals miR-9-3p as a novel tumor suppressor in gastric cancer</article-title>. <source>Oncotarget</source><year>2017</year>;<volume>8</volume>(<issue>23</issue>):<fpage>37321</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">28418879</pub-id></mixed-citation></ref><ref id="ref57"><label>57.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Macfarlane</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>PR</given-names></name></person-group>
<article-title>MicroRNA: biogenesis, function and role in cancer</article-title>. <source>Curr Genomics</source><year>2010</year>;<volume>11</volume>(<issue>7</issue>):<fpage>537</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">21532838</pub-id></mixed-citation></ref><ref id="ref58"><label>58.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kent</surname><given-names>OA</given-names></name>, <name name-style="western"><surname>Mendell</surname><given-names>JT</given-names></name></person-group>
<article-title>A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes</article-title>. <source>Oncogene</source><year>2006</year>;<volume>25</volume>(<issue>46</issue>):<fpage>6188</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">17028598</pub-id></mixed-citation></ref><ref id="ref59"><label>59.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>TF</given-names></name>, <name name-style="western"><surname>Mankaruos</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Scorilas</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma</article-title>. <source>J Urol</source><year>2010</year>;<volume>183</volume>(<issue>2</issue>):<fpage>743</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">20022054</pub-id></mixed-citation></ref><ref id="ref60"><label>60.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Henson</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wehbe-Janek</surname><given-names>H</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer</article-title>. <source>Gastroenterology</source><year>2007</year>;<volume>133</volume>(<issue>2</issue>):<fpage>647</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">17681183</pub-id></mixed-citation></ref><ref id="ref61"><label>61.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>ZX</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>R</given-names></name></person-group>
<article-title>MicroRNA-21: a novel therapeutic target in human cancer</article-title>. <source>Cancer Biol Ther</source><year>2010</year>;<volume>10</volume>(<issue>12</issue>):<fpage>1224</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">21139417</pub-id></mixed-citation></ref><ref id="ref62"><label>62.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Si</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>H</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1)</article-title>. <source>J Biol Chem</source><year>2007</year>;<volume>282</volume>(<issue>19</issue>):<fpage>14328</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">17363372</pub-id></mixed-citation></ref><ref id="ref63"><label>63.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Peralta-Zaragoza</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Deas</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Meneses-Acosta</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Relevance of miR-21 in regulation of tumor suppressor gene PTEN in human cervical cancer cells</article-title>. <source>BMC Cancer</source><year>2016</year>;<volume>16</volume>:<fpage>215</fpage>.<pub-id pub-id-type="pmid">26975392</pub-id></mixed-citation></ref><ref id="ref64"><label>64.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Gee</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Rose</surname><given-names>B</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Regulation of the tumour suppressor PDCD4 by miR-499 and miR-21 in oropharyngeal cancers</article-title>. <source>BMC Cancer</source><year>2016</year>;<volume>16</volume>:<fpage>86</fpage>.<pub-id pub-id-type="pmid">26867589</pub-id></mixed-citation></ref><ref id="ref65"><label>65.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Reis</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Pontes-Junior</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Antunes</surname><given-names>AA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer</article-title>. <source>BMC Urol</source><year>2012</year>;<volume>12</volume>:<fpage>14</fpage>.<pub-id pub-id-type="pmid">22642976</pub-id></mixed-citation></ref><ref id="ref66"><label>66.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Campos-Viguri</surname><given-names>GE</given-names></name>, <name name-style="western"><surname>Jimenez-Wences</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Peralta-Zaragoza</surname><given-names>O</given-names></name>, <etal>et al.</etal></person-group>
<article-title>miR-23b as a potential tumor suppressor and its regulation by DNA methylation in cervical cancer</article-title>. <source>Infect Agent Cancer</source><year>2015</year>;<volume>10</volume>:<fpage>42</fpage>.<pub-id pub-id-type="pmid">26622315</pub-id></mixed-citation></ref><ref id="ref67"><label>67.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tsuruta</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kozaki</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Uesugi</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer</article-title>. <source>Cancer Res</source><year>2011</year>;<volume>71</volume>(<issue>20</issue>):<fpage>6450</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">21868754</pub-id></mixed-citation></ref><ref id="ref68"><label>68.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>W</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MicroRNA-26a inhibits osteosarcoma cell proliferation by targeting IGF-1</article-title>. <source>Bone Res</source><year>2015</year>;<volume>3</volume>:<fpage>15033</fpage>.<pub-id pub-id-type="pmid">27468358</pub-id></mixed-citation></ref><ref id="ref69"><label>69.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>B</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Tumor-suppressive miR-26a and miR-26b inhibit cell aggressiveness by regulating FUT4 in colorectal cancer</article-title>. <source>Cell Death Dis</source><year>2017</year>;<volume>8</volume>(<issue>6</issue>):<fpage>1</fpage>&#x02013;<lpage>11</lpage>,<comment>e2892</comment>.<pub-id pub-id-type="pmid">29233966</pub-id></mixed-citation></ref><ref id="ref70"><label>70.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Goto</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kojima</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Nishikawa</surname><given-names>R</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer</article-title>. <source>Oncotarget</source><year>2014</year>;<volume>5</volume>(<issue>17</issue>):<fpage>7748</fpage>&#x02013;<lpage>59</lpage>.<pub-id pub-id-type="pmid">25115396</pub-id></mixed-citation></ref><ref id="ref71"><label>71.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Low expression of microRNA-30c promotes prostate cancer cells invasion involved in downregulation of KRAS protein</article-title>. <source>Oncol Lett</source><year>2017</year>;<volume>14</volume>(<issue>1</issue>):<fpage>363</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">28693177</pub-id></mixed-citation></ref><ref id="ref72"><label>72.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Karatas</surname><given-names>OF</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Shao</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group>
<article-title>miR-33a is a tumor suppressor microRNA that is decreased in prostate cancer</article-title>. <source>Oncotarget</source><year>2017</year>;<volume>8</volume>(<issue>36</issue>):<fpage>60243</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">28947967</pub-id></mixed-citation></ref><ref id="ref73"><label>73.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Majid</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Shao</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways</article-title>. <source>Clin Cancer Res</source><year>2013</year>;<volume>19</volume>(<issue>1</issue>):<fpage>73</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">23147995</pub-id></mixed-citation></ref><ref id="ref74"><label>74.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>Q</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Up-regulation of miR-95-3p in hepatocellular carcinoma promotes tumorigenesis by targeting p21 expression</article-title>. <source>Sci Rep</source><year>2016</year>;<volume>6</volume>:<fpage>1</fpage>&#x02013;<lpage>12</lpage>,<comment>34034</comment>.<pub-id pub-id-type="pmid">28442746</pub-id></mixed-citation></ref><ref id="ref75"><label>75.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Riquelme</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Tapia</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Leal</surname><given-names>P</given-names></name>, <etal>et al.</etal></person-group>
<article-title>miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway</article-title>. <source>Cell Oncol (Dordr)</source><year>2016</year>;<volume>39</volume>(<issue>1</issue>):<fpage>23</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">26458815</pub-id></mixed-citation></ref><ref id="ref76"><label>76.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Identification of active miRNA promoters from nuclear run-on RNA sequencing</article-title>. <source>Nucleic Acids Res</source><year>2017</year>;<volume>45</volume>(<issue>13</issue>):<fpage>e121</fpage>.<pub-id pub-id-type="pmid">28460090</pub-id></mixed-citation></ref><ref id="ref77"><label>77.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Imamura</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Komatsu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ichikawa</surname><given-names>D</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer</article-title>. <source>Sci Rep</source><year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>5708</fpage>.<pub-id pub-id-type="pmid">28720759</pub-id></mixed-citation></ref><ref id="ref78"><label>78.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hamada</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Satoh</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Fujibuchi</surname><given-names>W</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9</article-title>. <source>Mol Cancer Res</source><year>2012</year>;<volume>10</volume>(<issue>1</issue>):<fpage>3</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">22064652</pub-id></mixed-citation></ref><ref id="ref79"><label>79.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mets</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Van Peer</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Van Deer Meulen</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MicroRNA-128-3p is a novel oncomiR targeting PHF6 in T-cell acute lymphoblastic leukemia</article-title>. <source>Haematologica</source><year>2014</year>;<volume>99</volume>(<issue>8</issue>):<fpage>1326</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">24895337</pub-id></mixed-citation></ref><ref id="ref80"><label>80.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Tumor suppressor miR-128-3p inhibits metastasis and epithelial-mesenchymal transition by targeting ZEB1 in esophageal squamous-cell cancer</article-title>. <source>Acta Biochim Biophys Sin (Shanghai)</source><year>2018</year>;<volume>50</volume>(<issue>2</issue>):<fpage>171</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">29329360</pub-id></mixed-citation></ref><ref id="ref81"><label>81.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Papagiannakopoulos</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Friedmann-Morvinski</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Neveu</surname><given-names>P</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases</article-title>. <source>Oncogene</source><year>2012</year>;<volume>31</volume>(<issue>15</issue>):<fpage>1884</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">21874051</pub-id></mixed-citation></ref><ref id="ref82"><label>82.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kozaki</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Imoto</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Mogi</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer</article-title>. <source>Cancer Res</source><year>2008</year>;<volume>68</volume>(<issue>7</issue>):<fpage>2094</fpage>&#x02013;<lpage>105</lpage>.<pub-id pub-id-type="pmid">18381414</pub-id></mixed-citation></ref><ref id="ref83"><label>83.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Althoff</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Beckers</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Odersky</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A</article-title>. <source>Int J Cancer</source><year>2013</year>;<volume>133</volume>(<issue>5</issue>):<fpage>1064</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">23400681</pub-id></mixed-citation></ref><ref id="ref84"><label>84.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Tumor-suppressor role of miR-139-5p in endometrial cancer</article-title>. <source>Cancer Cell Int</source><year>2018</year>;<volume>18</volume>:<fpage>51</fpage>.<pub-id pub-id-type="pmid">29618950</pub-id></mixed-citation></ref><ref id="ref85"><label>85.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MiR-139-5p inhibits migration and invasion of colorectal cancer by downregulating AMFR and NOTCH1</article-title>. <source>Protein Cell</source><year>2014</year>;<volume>5</volume>(<issue>11</issue>):<fpage>851</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">25149074</pub-id></mixed-citation></ref><ref id="ref86"><label>86.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bischoff</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Huck</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Keller</surname><given-names>B</given-names></name>, <etal>et al.</etal></person-group>
<article-title>miR149 functions as a tumor suppressor by controlling breast epithelial cell migration and invasion</article-title>. <source>Cancer Res</source><year>2014</year>;<volume>74</volume>(<issue>18</issue>):<fpage>5256</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">25035394</pub-id></mixed-citation></ref><ref id="ref87"><label>87.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MicroRNA-153 functions as a tumor suppressor by targeting SET7 and ZEB2 in ovarian cancer cells</article-title>. <source>Oncol Rep</source><year>2015</year>;<volume>34</volume>(<issue>1</issue>):<fpage>111</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">25954928</pub-id></mixed-citation></ref><ref id="ref88"><label>88.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>F</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MiRNA-155 promotes proliferation by targeting caudal-type homeobox 1 (CDX1) in glioma cells</article-title>. <source>Biomed Pharmacother</source><year>2017</year>;<volume>95</volume>:<fpage>1759</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">28962081</pub-id></mixed-citation></ref><ref id="ref89"><label>89.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Due</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Svendsen</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bodker</surname><given-names>JS</given-names></name>, <etal>et al.</etal></person-group>
<article-title>miR-155 as a biomarker in B-cell malignancies</article-title>. <source>Biomed Res Int</source><year>2016</year>;<volume>2016</volume>:<fpage>1</fpage>&#x02013;<lpage>14</lpage>,<comment>9513037</comment>.</mixed-citation></ref><ref id="ref90"><label>90.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tili</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Svendsen</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bodker</surname><given-names>JS</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock</article-title>. <source>J Immunol</source><year>2007</year>;<volume>179</volume>(<issue>8</issue>):<fpage>5082</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">17911593</pub-id></mixed-citation></ref><ref id="ref91"><label>91.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>O'Connell</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Chaudhuri</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Rao</surname><given-names>DS</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Inositol phosphatase SHIP1 is a primary target of miR-155</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2009</year>;<volume>106</volume>(<issue>17</issue>):<fpage>7113</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">19359473</pub-id></mixed-citation></ref><ref id="ref92"><label>92.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yue</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Breschi</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A comparative encyclopedia of DNA elements in the mouse genome</article-title>. <source>Nature</source><year>2014</year>;<volume>515</volume>(<issue>7527</issue>):<fpage>355</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">25409824</pub-id></mixed-citation></ref><ref id="ref93"><label>93.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Sossey-Alaoui</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>CL</given-names></name>, <etal>et al.</etal></person-group>
<article-title>TGF-beta upregulates miR-181a expression to promote breast cancer metastasis</article-title>. <source>J Clin Invest</source><year>2013</year>;<volume>123</volume>(<issue>1</issue>):<fpage>150</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">23241956</pub-id></mixed-citation></ref><ref id="ref94"><label>94.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Dong-Xu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Jia</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Su-Juan</surname><given-names>Z</given-names></name></person-group>
<article-title>MicroRNA-185 is a novel tumor suppressor by negatively modulating the Wnt/beta-catenin pathway in human colorectal cancer</article-title>. <source>Indian J Cancer</source><year>2015</year>;<volume>52</volume>(<issue>Suppl 3</issue>):<fpage>E182</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">27453420</pub-id></mixed-citation></ref><ref id="ref95"><label>95.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hui</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Jian</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Z</given-names></name>, <etal>et al</etal></person-group>
<article-title>MiR-186 acts as a tumor suppressor by targeting TWIST1/2 and regulating the epithelial-mesenchymal transition in glioblastoma multiforme</article-title>. <source>Int J Clin Exp Pathol</source><year>2016</year>;<volume>9</volume>(<issue>9</issue>):<fpage>9706</fpage>&#x02013;<lpage>14</lpage>.</mixed-citation></ref><ref id="ref96"><label>96.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>B</given-names></name>, <etal>et al.</etal></person-group>
<article-title>miR-198 functions as a tumor suppressor in breast cancer by targeting CUB domain-containing protein 1</article-title>. <source>Oncol Lett</source><year>2017</year>;<volume>13</volume>(<issue>3</issue>):<fpage>1753</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">28454320</pub-id></mixed-citation></ref><ref id="ref97"><label>97.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-kappaB signaling pathway</article-title>. <source>Mol Cancer</source><year>2017</year>;<volume>16</volume>(<issue>1</issue>):<fpage>117</fpage>.<pub-id pub-id-type="pmid">28693582</pub-id></mixed-citation></ref><ref id="ref98"><label>98.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>F</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Tumor-suppressing roles of miR-214 and miR-218 in breast cancer</article-title>. <source>Oncol Rep</source><year>2016</year>;<volume>35</volume>(<issue>6</issue>):<fpage>3178</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">27109339</pub-id></mixed-citation></ref><ref id="ref99"><label>99.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hashimoto</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Akiyama</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yuasa</surname><given-names>Y</given-names></name></person-group>
<article-title>Multiple-to-multiple relationships between microRNAs and target genes in gastric cancer</article-title>. <source>PLoS One</source><year>2013</year>;<volume>8</volume>(<issue>5</issue>):<fpage>1</fpage>&#x02013;<lpage>11</lpage>,<comment>e62589</comment>.</mixed-citation></ref><ref id="ref100"><label>100.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>miR-326 targets CCND1 and inhibits non-small cell lung cancer development</article-title>. <source>Oncotarget</source><year>2016</year>;<volume>7</volume>(<issue>7</issue>):<fpage>8341</fpage>&#x02013;<lpage>59</lpage>.<pub-id pub-id-type="pmid">26840018</pub-id></mixed-citation></ref><ref id="ref101"><label>101.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Scarola</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Schoeftner</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>C</given-names></name>, <etal>et al.</etal></person-group>
<article-title>miR-335 directly targets Rb1 (pRb/p105) in a proximal connection to p53-dependent stress response</article-title>. <source>Cancer Res</source><year>2010</year>;<volume>70</volume>(<issue>17</issue>):<fpage>6925</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">20713524</pub-id></mixed-citation></ref><ref id="ref102"><label>102.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cai</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>D</given-names></name>, <etal>et al.</etal></person-group>
<article-title>miR-335 represents an invasion suppressor gene in ovarian cancer by targeting Bcl-w</article-title>. <source>Oncol Rep</source><year>2013</year>;<volume>30</volume>(<issue>2</issue>):<fpage>701</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">23708561</pub-id></mixed-citation></ref><ref id="ref103"><label>103.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sandoval-Borquez</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Polakovicova</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Carrasco-Veliz</surname><given-names>N</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MicroRNA-335-5p is a potential suppressor of metastasis and invasion in gastric cancer</article-title>. <source>Clin Epigenetics</source><year>2017</year>;<volume>9</volume>:<fpage>114</fpage>.<pub-id pub-id-type="pmid">29075357</pub-id></mixed-citation></ref><ref id="ref104"><label>104.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>C</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MiR-335 acts as a potential tumor suppressor miRNA via downregulating ROCK1 expression in hepatocellular carcinoma</article-title>. <source>Tumour Biol</source><year>2015</year>;<volume>36</volume>(<issue>8</issue>):<fpage>6313</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">25804796</pub-id></mixed-citation></ref><ref id="ref105"><label>105.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>Q</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MicroRNA-338-3p functions as tumor suppressor in breast cancer by targeting SOX4</article-title>. <source>Int J Oncol</source><year>2015</year>;<volume>47</volume>(<issue>4</issue>):<fpage>1594</fpage>&#x02013;<lpage>602</lpage>.<pub-id pub-id-type="pmid">26252944</pub-id></mixed-citation></ref><ref id="ref106"><label>106.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>ZS</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>CQ</given-names></name>, <etal>et al.</etal></person-group>
<article-title>miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met</article-title>. <source>Cancer</source><year>2011</year>;<volume>117</volume>(<issue>13</issue>):<fpage>2842</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">21692045</pub-id></mixed-citation></ref><ref id="ref107"><label>107.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Grady</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Parkin</surname><given-names>RK</given-names></name>, <name name-style="western"><surname>Mitchell</surname><given-names>PS</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Epigenetic silencing of the intronic microRNA miR-342 and its host gene EVL in colorectal cancer</article-title>. <source>Oncogene</source><year>2008</year>;<volume>27</volume>(<issue>27</issue>):<fpage>3880</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">18264139</pub-id></mixed-citation></ref><ref id="ref108"><label>108.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Qing</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MiR-346 suppresses cell proliferation through SMYD3 dependent approach in hepatocellular carcinoma</article-title>. <source>Oncotarget</source><year>2017</year>;<volume>8</volume>(<issue>39</issue>):<fpage>65218</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">29029425</pub-id></mixed-citation></ref><ref id="ref109"><label>109.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bai</surname><given-names>L</given-names></name></person-group>
<article-title>MicroRNA-449a functions as a tumor suppressor in pancreatic cancer by the epigenetic regulation of ATDC expression</article-title>. <source>Biomed Pharmacother</source><year>2018</year>;<volume>103</volume>:<fpage>782</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">29684857</pub-id></mixed-citation></ref><ref id="ref110"><label>110.</label><mixed-citation publication-type="other">
<person-group person-group-type="author"><name name-style="western"><surname>Budd</surname><given-names>W</given-names></name></person-group>
<article-title>Combinatorial analysis of tumorigenic microRNAs driving prostate cancer</article-title>. <comment>PhD diss., Virginia Commonwealth University</comment>, <year>2012</year>.</mixed-citation></ref><ref id="ref111"><label>111.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Downregulated miR-486-5p acts as a tumor suppressor in esophageal squamous cell carcinoma</article-title>. <source>Exp Ther Med</source><year>2016</year>;<volume>12</volume>(<issue>5</issue>):<fpage>3411</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">27882172</pub-id></mixed-citation></ref><ref id="ref112"><label>112.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ke</surname><given-names>X</given-names></name>, <etal>et al.</etal></person-group>
<article-title>miR-488 acts as a tumor suppressor gene in gastric cancer</article-title>. <source>Tumour Biol</source><year>2016</year>;<volume>37</volume>(<issue>7</issue>):<fpage>8691</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">26738864</pub-id></mixed-citation></ref><ref id="ref113"><label>113.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Ji</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>F</given-names></name>, <etal>et al</etal></person-group>
<article-title>miR-489 acts as a tumor suppressor in human gastric cancer by targeting PROX1</article-title>. <source>Am J Cancer Res</source><year>2016</year>;<volume>6</volume>(<issue>9</issue>):<fpage>2021</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">27725907</pub-id></mixed-citation></ref><ref id="ref114"><label>114.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nakano</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Miyazawa</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kinoshita</surname><given-names>K</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells</article-title>. <source>Int J Cancer</source><year>2010</year>;<volume>127</volume>(<issue>5</issue>):<fpage>1072</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">20039318</pub-id></mixed-citation></ref><ref id="ref115"><label>115.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>R</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Negative regulation of tumor suppressor p53 by microRNA miR-504</article-title>. <source>Mol Cell</source><year>2010</year>;<volume>38</volume>(<issue>5</issue>):<fpage>689</fpage>&#x02013;<lpage>99</lpage>.<pub-id pub-id-type="pmid">20542001</pub-id></mixed-citation></ref><ref id="ref116"><label>116.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kikkawa</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Kinoshita</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Nohata</surname><given-names>N</given-names></name>, <etal>et al.</etal></person-group>
<article-title>microRNA-504 inhibits cancer cell proliferation via targeting CDK6 in hypopharyngeal squamous cell carcinoma</article-title>. <source>Int J Oncol</source><year>2014</year>;<volume>44</volume>(<issue>6</issue>):<fpage>2085</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">24647829</pub-id></mixed-citation></ref><ref id="ref117"><label>117.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Guan</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>C</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A tumor-suppressive microRNA, miR-504, inhibits cell proliferation and promotes apoptosis by targeting FOXP1 in human glioma</article-title>. <source>Cancer Lett</source><year>2016</year>;<volume>374</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">26854715</pub-id></mixed-citation></ref><ref id="ref118"><label>118.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Leivonen</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Salhberg</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Makela</surname><given-names>R</given-names></name>, <etal>et al.</etal></person-group>
<article-title>High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth</article-title>. <source>Mol Oncol</source><year>2014</year>;<volume>8</volume>(<issue>1</issue>):<fpage>93</fpage>&#x02013;<lpage>104</lpage>.<pub-id pub-id-type="pmid">24148764</pub-id></mixed-citation></ref><ref id="ref119"><label>119.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Png</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Yoshida</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>XH</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer</article-title>. <source>Genes Dev</source><year>2011</year>;<volume>25</volume>(<issue>3</issue>):<fpage>226</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">21289068</pub-id></mixed-citation></ref><ref id="ref120"><label>120.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>YS</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>CD</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Up-regulation of CRKL by microRNA-335 methylation is associated with poor prognosis in gastric cancer</article-title>. <source>Cancer Cell Int</source><year>2017</year>;<volume>17</volume>:<fpage>28</fpage>.<pub-id pub-id-type="pmid">28239297</pub-id></mixed-citation></ref><ref id="ref121"><label>121.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Petrocca</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Vecchione</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Croce</surname><given-names>CM</given-names></name></person-group>
<article-title>Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling</article-title>. <source>Cancer Res</source><year>2008</year>;<volume>68</volume>(<issue>20</issue>):<fpage>8191</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">18922889</pub-id></mixed-citation></ref><ref id="ref122"><label>122.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kristensen</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Haldrup</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Strand</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy</article-title>. <source>Clin Cancer Res</source><year>2014</year>;<volume>20</volume>(<issue>8</issue>):<fpage>2169</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">24737792</pub-id></mixed-citation></ref><ref id="ref123"><label>123.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Tahara</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Malik</surname><given-names>P</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Involvement of miR-30c and miR-301a in immediate induction of plasminogen activator inhibitor-1 by placental growth factor in human pulmonary endothelial cells</article-title>. <source>Biochem J</source><year>2011</year>;<volume>434</volume>(<issue>3</issue>):<fpage>473</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">21175428</pub-id></mixed-citation></ref><ref id="ref124"><label>124.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>XZ</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>XL</given-names></name>, <name name-style="western"><surname>Xiao</surname><given-names>WZ</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Downregulation of VMP1 confers aggressive properties to colorectal cancer</article-title>. <source>Oncol Rep</source><year>2015</year>;<volume>34</volume>(<issue>5</issue>):<fpage>2557</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">26328607</pub-id></mixed-citation></ref><ref id="ref125"><label>125.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Gambari</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Brognara</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Spandidos</surname><given-names>DA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: new trends in the development of miRNA therapeutic strategies in oncology (Review)</article-title>. <source>Int J Oncol</source><year>2016</year>;<volume>49</volume>(<issue>1</issue>):<fpage>5</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">27175518</pub-id></mixed-citation></ref><ref id="ref126"><label>126.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>DD</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>S</given-names></name></person-group>
<article-title>Development of novel therapeutic agents by inhibition of oncogenic microRNAs</article-title>. <source>Int J Mol Sci</source><year>2017</year>;<volume>19</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>17</lpage>.</mixed-citation></ref><ref id="ref127"><label>127.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Daniunaite</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Dubikaityte</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gibas</surname><given-names>P</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Clinical significance of miRNA host gene promoter methylation in prostate cancer</article-title>. <source>Hum Mol Genet</source><year>2017</year>;<volume>26</volume>(<issue>13</issue>):<fpage>2451</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">28398479</pub-id></mixed-citation></ref><ref id="ref128"><label>128.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Meng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>HL</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer</article-title>. <source>Proc Natl Acad Sci U S A</source>, <year>2015</year>;<volume>112</volume>(<issue>31</issue>):<fpage>E4288</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">26187928</pub-id></mixed-citation></ref><ref id="ref129"><label>129.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kasar</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Underbayev</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia</article-title>. <source>Oncogene</source><year>2014</year>;<volume>33</volume>(<issue>25</issue>):<fpage>3307</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">23995789</pub-id></mixed-citation></ref><ref id="ref130"><label>130.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Friedman</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Chihara</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells</article-title>. <source>Biochem Biophys Res Commun</source><year>2009</year>;<volume>379</volume>(<issue>3</issue>):<fpage>726</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">19116145</pub-id></mixed-citation></ref><ref id="ref131"><label>131.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Garzon</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Marcucci</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Croce</surname><given-names>CM</given-names></name></person-group>
<article-title>Targeting microRNAs in cancer: rationale, strategies and challenges</article-title>. <source>Nat Rev Drug Discov</source><year>2010</year>;<volume>9</volume>(<issue>10</issue>):<fpage>775</fpage>&#x02013;<lpage>89</lpage>.<pub-id pub-id-type="pmid">20885409</pub-id></mixed-citation></ref><ref id="ref132"><label>132.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>B</given-names></name>, <etal>et al.</etal></person-group>
<article-title>An artificially designed interfering lncRNA expressed by oncolytic adenovirus competitively consumes oncomiRs to exert antitumor efficacy in hepatocellular carcinoma</article-title>. <source>Mol Cancer Ther</source><year>2016</year>;<volume>15</volume>(<issue>7</issue>):<fpage>1436</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">27196772</pub-id></mixed-citation></ref><ref id="ref133"><label>133.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Price</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name></person-group>
<article-title>MicroRNAs in cancer biology and therapy: current status and perspectives</article-title>. <source>Genes Dis</source><year>2014</year>;<volume>1</volume>(<issue>1</issue>):<fpage>53</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">25473652</pub-id></mixed-citation></ref></ref-list></back></article>